Mutant piggyBac transposase
By replacing piggyBac transposase at specific positions, improving its stability in host cells, the problem of insufficient titer and stability of recombinant protein expression in the prior art is solved, and more efficient biopharmaceutical production is achieved.
Patent Information
- Application Number
- CN202411173681.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-10-24
- Filing Date
- 2019-12-09
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art is difficult to effectively improve the expression titer and stability of recombinant proteins in host cells, resulting in high cost and long time for biopharmaceutical development and increased product line complexity. A method is needed to improve the efficiency of protein expression systems.
Improve its in-host by performing amino acid substitution of piggyBac transposase, especially in positions 147, 176, 221, 247, 429, 533 and 573, in order to replace serine by leucine on isoleucine or threonine on the serine in the host Stability in cells, thereby enhancing the expression titer of recombinant proteins.
Through these amino acid substitutions, the expression titer of recombinant proteins is significantly improved. Compared with the use of wild-type piggyBac transposase, the engineered transposase significantly improves the expression level of the target protein in the host cell and improves the efficiency of biopharmaceutical production and stability.
Smart Images

Figure CN118995660A_ABST
Abstract
Description
[0001] This application is a divisional application of the invention patent with application date of December 9, 2019, application number 201980081292.7, and invention name “Mutant piggyBac transposase”.
[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 777,325, filed December 10, 2018, and U.S. Provisional Application No. 62 / 925,516, filed October 24, 2019, which are hereby incorporated by reference in their entirety and for all purposes as if fully set forth herein. Technical Field
[0003] The present invention relates to piggyBac transposases engineered to increase their stability in cells, and the use of these engineered piggyBac transposases in stably transfecting cells, cell line development, genome modification, and improving recombinant protein titers. Background Art
[0004] Due to their widespread application, biologics are used worldwide in a variety of applications, such as therapeutics and diagnostics. Currently, approximately 51% of approved biologics are produced using mammalian cells, with Chinese hamster ovary (CHO) cells being the primary cell factory (Zhou and Kantardjeff, Mammalian cell cultures for biologics manufacturing, Springer, Heidelberg, NY, 2014). As a result, the biopharmaceutical industry is undergoing a rapid paradigm shift. Speed to market and cost-efficiency are now more critical than ever. The high R&D costs and long development lead times of biologic drugs necessitate eliminating delays and inefficiencies in drug development and, more importantly, manufacturing. Simultaneously, with the increasing complexity and diversity of product pipelines, biopharmaceutical companies now require infrastructure that can accommodate diverse models, from personalized therapies derived from donor cells to the production of biologic drugs in quantities ranging from a few grams to hundreds of kilograms per year.
[0005] Therefore, there is a need to increase the production of recombinant proteins from host cells and improve the long-term stability of expression. One way to achieve this goal is to improve the titer of proteins expressed by cellular expression systems. The invention described herein provides mutations that help increase the stability of piggyBac transposases expressed in host cells. It has been found that piggyBac transposases encoded by nucleic acid sequences engineered with such mutations result in improved titers of recombinant proteins expressed in cells containing the engineered piggyBac transposase, compared to the titers of recombinant proteins expressed in cells containing wild-type piggyBac transposase or cells not engineered with piggyBac transposase. Summary of the Invention
[0006] In one aspect, the present invention provides a piggyBac transposase comprising an amino acid substitution at one or more of positions 147, 176, 221, 247, 429, 533, and 573 of SEQ ID NO: 2. In one embodiment, the piggyBac transposase comprises an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO: 2. In one embodiment, the piggyBac transposase comprises an amino acid substitution of threonine for serine at one or more of positions 429, 533, and 573 of SEQ ID NO: 2. In one embodiment, the piggyBac transposase comprises an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO: 2, and / or a threonine for serine at one or more of positions 429, 533, and 573 of SEQ ID NO: 2. In related embodiments, the piggyBac transposase comprises at least one of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO: 2. In related embodiments, the piggyBac transposase comprises at least two of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO: 2. In another related embodiment, the piggyBac transposase comprises a substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, a substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and a substitution of threonine for serine at position 533 of SEQ ID NO: 2. In one embodiment, the piggyBac transposase improves the titer of a recombinant protein of interest expressed by cells transfected with an engineered piggyBac transposase as described herein, compared to the titer of the same protein of interest expressed by cells transfected with wild-type piggyBac transposase or not transfected with piggyBac transposase. In one embodiment, the recombinant protein of interest is an antigen binding protein.
[0007] In one aspect, the invention provides a piggyBac transposase engineered for increased stability in a host cell, wherein the piggyBac transposase comprises an amino acid substitution at one or more of positions 147, 176, 221, 247, 429, 533, and 573 of SEQ ID NO:2.
[0008] In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, or SEQ ID NO: 8. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 12. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 4. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 6. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 8. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 10. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 12. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 14. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 16.
[0009] In another aspect, the present invention provides an engineered nucleic acid molecule encoding a piggyBac transposase as described herein. In another aspect, the present invention provides a piggyBac transposase encoded by a nucleic acid sequence of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, or SEQ ID NO:18. In another aspect, the present invention provides a piggyBac transposase encoded by a nucleic acid sequence of SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7. In another aspect, the present invention provides a piggyBac transposase encoded by a nucleic acid sequence of SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15. In another aspect, the present invention provides a piggyBac transposase encoded by a nucleic acid sequence of SEQ ID NO:9 or SEQ ID NO:11. In another aspect, the present invention provides a piggyBac transposase encoded by a nucleic acid sequence of SEQ ID NO:17 or SEQ ID NO:18. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:5. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:7. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:9. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:11. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:13. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:15. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:17. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:18.
[0010] In another aspect, the present invention provides a vector comprising a nucleic acid molecule encoding a piggyBac transposase as described herein. In one embodiment, the vector comprises a nucleic acid molecule encoding a piggyBac transposase as described herein and further comprises at least one nucleic acid sequence encoding at least one protein of interest, the protein of interest being flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon. In one embodiment, the vector comprises one or more nucleic acid sequences encoding one or more proteins of interest.
[0011] In another aspect, the present invention provides a cell transfected with a vector as described herein. In one embodiment, the cell is transfected with a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 17 or 18. In one embodiment, the cell is a host cell. In one embodiment, the cell is a CHO cell. In one embodiment, the cell is an immune cell.
[0012] In another aspect, the present invention provides cells co-transfected with an engineered nucleic acid molecule encoding a piggyBac transposase as described herein and a vector comprising at least one nucleic acid molecule encoding at least one protein of interest, the protein of interest being flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon. In another embodiment, the present invention provides cells co-transfected with an engineered nucleic acid molecule encoding a piggyBac transposase as described herein and a vector comprising at least one nucleic acid molecule encoding at least one protein of interest, the protein of interest being flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon. In another embodiment, the present invention provides cells co-transfected with an engineered nucleic acid molecule encoding a piggyBac transposase as described herein and a vector comprising at least one nucleic acid molecule encoding at least one protein of interest, the protein of interest being flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon.
[0013] In another aspect, the present invention provides a cell as described herein, wherein the titer of a protein of interest expressed by cells transfected with an engineered piggyBac transposase is improved compared to the titer of the same protein of interest expressed by cells transfected with wild-type piggyBac transposase or not transfected with piggyBac transposase. In one embodiment, a recombinant protein of interest expressed by the cell is provided. In a related embodiment, a pharmaceutical composition comprising the recombinant protein of interest is provided.
[0014] In another aspect, the present invention provides a method for improving the titer of a recombinant protein of interest expressed in a host cell, the method comprising engineering a nucleic acid molecule encoding a piggyBac transposase to increase its stability in the host cell; co-transfecting the host cell with the engineered nucleic acid molecule encoding the piggyBac transposase and a vector comprising a nucleic acid sequence encoding a protein of interest flanked by at least 5' and 3' inverted repeat elements of the piggyBac transposon; and culturing the cells to express the recombinant protein of interest, wherein the titer of the recombinant protein of interest expressed by the host cell transfected with the engineered piggyBac transposase is improved compared to the titer of the recombinant protein of interest expressed by the host cell transfected with wild-type piggyBac transposase or not transfected with the piggyBac transposase. In one embodiment, the host cell is transfected with a first vector comprising the engineered nucleic acid molecule encoding the piggyBac transposase and a second vector comprising a nucleic acid sequence encoding the protein of interest flanked by at least 5' and 3' inverted repeat elements of the piggyBac transposon. In one embodiment, the host cell is transfected with a single vector comprising an engineered nucleic acid molecule encoding a piggyBac transposase and a nucleic acid sequence encoding a protein of interest flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon.
[0015] In another aspect, the present invention provides a method for increasing production of a recombinant protein in a mammalian cell culture expressing a recombinant protein, the method comprising establishing a cell culture in a bioreactor using host cells that have been co-transfected with a nucleic acid molecule encoding a piggyBac transposase engineered for increased stability in the host cell and a vector comprising a nucleic acid molecule encoding a protein of interest flanked by at least inverted repeat elements of the piggyBac transposon; and expressing the recombinant protein of interest; wherein the titer of the recombinant protein of interest expressed by the host cells transfected with the engineered piggyBac transposase is improved compared to the titer of the recombinant protein of interest expressed by host cells transfected with wild-type piggyBac transposase or not transfected with the piggyBac transposase. In one embodiment, the host cell has been co-transfected with a vector comprising a nucleic acid molecule encoding a piggyBac transposase engineered for increased stability in the host cell and a vector comprising a nucleic acid molecule encoding a protein of interest, the protein of interest being flanked by at least the inverted repeat elements of the piggyBac transposon; in one embodiment, the host cell is transfected with a single vector comprising an engineered nucleic acid molecule encoding the piggyBac transposase and a nucleic acid sequence encoding the protein of interest, the protein of interest being flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon.
[0016] In another aspect, the present invention provides a method for producing an isolated and purified recombinant protein of interest, the method comprising establishing a cell culture in a bioreactor with host cells expressing the recombinant protein of interest, wherein the cell line has been co-transfected with a nucleic acid sequence encoding a piggyBac transposase engineered for increased stability in the host cell and a vector comprising a nucleic acid sequence encoding the protein of interest, the nucleic acid sequence encoding the piggyBac transposase being engineered for increased stability in the host cell, and the protein of interest being flanked by at least 5' and 3' inverted repeat elements of the piggyBac transposon; culturing the cells to express the recombinant protein of interest; harvesting the recombinant protein of interest, processing the recombinant protein of interest through one or more unit operations, and obtaining an isolated and purified recombinant protein of interest. In one embodiment, the cell line has been co-transfected with a vector comprising a nucleic acid sequence encoding the piggyBac transposase engineered for increased stability in the host cell and a vector comprising a nucleic acid sequence encoding the protein of interest, the nucleic acid sequence encoding the piggyBac transposase being engineered for increased stability in the host cell, and the protein of interest being flanked by at least 5' and 3' inverted repeat elements of the piggyBac transposon. In one embodiment, the host cell is transfected with a single vector comprising an engineered nucleic acid molecule encoding a piggyBac transposase and a nucleic acid sequence encoding a protein of interest flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon. In one embodiment, at least one unit operation is a capture chromatography step selected from affinity chromatography, ion exchange chromatography, anion exchange chromatography, cation exchange chromatography, multimodal chromatography, hydrophobic interaction chromatography, and hydroxyapatite chromatography. In a related embodiment, at least one unit operation is a polish chromatography step selected from ion exchange chromatography, anion exchange chromatography, cation exchange chromatography, multimodal chromatography, hydrophobic interaction chromatography, and hydroxyapatite chromatography. In one embodiment, at least one unit operation is selected from viral inactivation, viral filtration, depth filtration, and UF / DF. In one embodiment, the titer of the recombinant protein of interest expressed by host cells transfected with the engineered piggyBac transposase is improved compared to the titer of the recombinant protein of interest expressed by host cells transfected with wild-type piggyBac transposase or not transfected with piggyBac transposase. In one embodiment, the recombinant protein is isolated and purified. In a related embodiment is a pharmaceutical composition comprising the isolated protein of interest.
[0017] In one aspect, the present invention provides a kit for transfecting cells, the kit comprising a vector comprising a nucleic acid sequence encoding a piggyBac transposase, wherein the nucleic acid sequence encoding the piggyBac transposase is engineered to increase stability in the host cell; and a vector comprising at least the 5' and 3' inverted repeat elements of the piggyBac transposon, wherein at least one nucleic acid sequence encoding at least one protein of interest is inserted into the piggyBac transposon.
[0018] In one aspect, the present invention provides a method for producing non-virally genetically modified cells, the method comprising: (a) creating a vector comprising a nucleic acid sequence encoding a piggyBac transposase, the nucleic acid sequence encoding the piggyBac transposase being engineered for increased stability in the cell, and at least one nucleic acid sequence encoding at least one protein of interest, the protein of interest being flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon; (b) isolating natural immune cells from a donor or subject; (c) transfecting the cells with the vector and the nucleic acid sequence encoding the piggyBac transposase being engineered for increased stability in the cell; and (c) expanding the cells into a larger population of non-virally genetically modified cells by cell culture. In one embodiment, the cells are transfected with a vector comprising at least one nucleic acid sequence encoding at least one protein of interest flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon and a vector comprising a nucleic acid sequence encoding a piggyBac transposase, the nucleic acid sequence encoding the piggyBac transposase being engineered for increased stability in the cell. In one embodiment, the cells are transfected with a vector comprising at least one nucleic acid sequence encoding at least one protein of interest flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon and a nucleic acid sequence encoding the piggyBac transposase being engineered for increased stability in the cell.
[0019] In one aspect, the present invention provides a method for treating a subject with non-viral genetically modified cells, the method comprising: (a) creating a vector comprising at least one nucleic acid sequence encoding at least one protein of interest flanked by at least the 5' and 3' inverted repeat elements of a piggyBac transposon; (b) isolating natural immune cells from a subject or donor; (c) transfecting the cells with the vector and a nucleic acid sequence encoding a piggyBac transposase engineered for increased stability in the cells; (d) expanding the cells into a larger population of genetically modified cells by cell culture; (e) isolating the transformed cells from the cell culture to obtain a cell population comprising the genetically modified cells; and (f) reintroducing the non-viral genetically modified cells into the subject. In one embodiment, the cells are transfected with a vector comprising at least one nucleic acid sequence encoding at least one protein of interest flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon and a vector comprising a nucleic acid sequence encoding a piggyBac transposase, the nucleic acid sequence encoding the piggyBac transposase being engineered to increase stability in the cell. In one embodiment, the cells are transfected with a vector comprising at least one nucleic acid sequence encoding at least one protein of interest flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon and a nucleic acid sequence encoding the piggyBac transposase, the nucleic acid sequence encoding the piggyBac transposase being engineered to increase stability in the cell. In one embodiment, the innate immune cell is a monocyte. In one embodiment, the innate immune cell is a T cell. In one embodiment, the at least one protein of interest is an antigen receptor, a T cell receptor, or a chimeric antigen receptor. In one embodiment, the cells are also transfected with a nucleic acid molecule encoding a suicide gene, i.e., an inducible on or accelerator switch, or both. In one embodiment, the cells, cell population, or cell culture are non-virally genetically modified. In one embodiment, a formulation comprising a genetically modified cell or cell population. In another embodiment, a method of treating or preventing a disease or disorder in a donor or subject in need thereof comprises administering to the donor or subject an effective amount of the genetically modified cells or cell population. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 : Predicted secondary structure. The horizontal bars indicate predicted α-helical regions, and the arrows indicate predicted β-sheet regions.
[0021] Figure 2 For mAbs AB1 and AB2, the titers of the engineered piggyBac transposase cell lines were improved or comparable to those of the WT piggyBac transposase or the no-piggyBac transposase control.
[0022] Figure 3 : For cell lines expressing fusion proteins, the titer of engineered piggyBac transposase cell lines was improved compared to WT piggyBac transposase or no piggyBac transposase control.
[0023] Figure 4 : For bispecific T cell engager molecules, the titers of engineered piggyBac transposase cell lines were comparable to WT piggyBac transposase or a no piggyBac transposase control.
[0024] Figure 5 : Pools transfected with the piggybac transposase double mutant "ILT" or triple mutant "LLT" transposase showed increased expression compared to those transposase pools that did not receive MSX treatment (0 μM MSX). For these pools to which no transposase was added (None), expression did not increase with the addition of MSX. HeteroFc, IgGscFV and mAb. MSX was added at the time of transfection (25) or after recovery of the initial DNA transposase transfection pool (0-25).
[0025] Figure 6A and 6B Pool expression levels relative to piggyBac transposase double mutant "ILT" DNA or mRNA transfected using electroporation or lipid-based methods.
[0026] 6A) Electroporation-based transfection method comparing DNA transposase and mRNA transposase. Adding mRNA transposase improves expression. 1) 0 μg transposase, 20 μg mAb DNA; 2) double mutant "ILT" DNA: 20 μg mAb DNA, 5 μg transposase, ratio of 4:1; 3) double mutant "ILT" mRNA 20 μg mAb DNA, 5 μg transposase, ratio of 4:1; 4) double mutant "ILT" mRNA 20 μg mAb DNA, 10 μg transposase, ratio of 2:1; 5) double mutant "ILT" mRNA 20 μg mAb DNA, 20 μg transposase, ratio of 1:1; 11) double mutant "ILT" mRNA 14 μg mAb DNA, 100 μg transposase, ratio of 7:1; 12) double mutant "ILT" mRNA 28 μg mAb DNA, 200 μg transposase, ratio of 7:1.
[0027] 6B): Lipid-based transfection method comparing DNA transposase and mRNA transposase. Adding mRNA transposase improved expression. PiggyBac transposase double mutant "ILT" DNA: 2 μg mAb DNA, 0.5 μg transposase, 4:1 ratio; 2 μg mAb DNA, 2 μg transposase, 1:1 ratio; 4 μg mAb DNA, 4 μg transposase, 1:1 ratio; PiggyBac transposase double mutant "ILT" mRNA: 2 μg mAb DNA, 0.5 μg transposase, 4:1 ratio; 2 μg mAb DNA, 2 μg transposase, 1:1 ratio; 4 μg mAb DNA, 4 μg transposase, 1:1 ratio.
[0028] Figure 7 Expression levels in electroporated transfected pools. Transfection of the double-mutant transposase "ILT" DNA and two mRNAs. Titers in the synthetic mRNA (PB syn mRNA) and mRNA (PB mRNA) transfected pools were similar to those in the DNA (PB DNA) transposase pool and higher than those in the no-transposase control pool. Downward arrows indicate minimum values. Upward arrows indicate maximum values. White bars indicate medians.
[0029] Figure 8A and 8B : Genomic and transcriptional integration of DNA and mRNA in a pool of transfected cell lines.
[0030] 8A) All pooled cell lines transfected with the double mutant "ILT" DNA transposase had genomic integration, whereas those transfected with mRNA did not. A band of approximately 1.7 kb indicates the presence of the transposase in the genome of this cell line. Lane 1: ladder. Lanes 2-4: piggyBac transposase double mutant "ILT" DNA. Lane 5: no transfection. Lanes 6-11: piggyBac transposase double mutant "ILT" mRNA. Lane 12: plasmid DNA control.
[0031] 8B) Gel image of an RT-PCR assay examining RNA-level transcription. All pooled cell lines transfected with the double-mutant "ILT" DNA transposase exhibited RNA-level transcription, whereas those transfected with mRNA lacked RNA-level transcription. A band of approximately 1.7 kb indicates the presence of this transposase transcript. Lane 1: Ladder. Lanes 2-3: piggyBac transposase double-mutant "ILT" mRNA. Lane 4: piggyBac transposase double-mutant "ILT" DNA. Lane 5: Plasmid DNA control.
[0032] Figure 9 This pool has a lower copy number and contains clones that have not integrated the transposase.
[0033] Figure 10. TCR-T cells generated using nonviral gene delivery and piggyBac transposase exhibit robust in vitro functionality. (A) T cells were successfully engineered to express TCRs using double-mutant ILTs. (B) Target cell lysis and (C) proliferation of piggyBac-engineered TCR-T cells after 5 days of incubation with antigen-presenting cells. DETAILED DESCRIPTION
[0034] DNA transposons or transposable elements are genetic elements that can move from one location in the host genome to another. Transposable elements are typically divided into two categories, the first of which is represented by retrotransposons, and the second category includes "cut and paste" DNA transposons.
[0035] Class 2 DNA transposons are characterized by their two components: a transposon containing a DNA segment flanked by two inverted terminal repeats, and a transposase that catalyzes the movement of the transposon. The transposase functions by binding to the inverted repeats, excising the DNA segment flanked by the terminal inverted repeats (cleaving the segment), and reintegrating the segment into a new location (pasting the segment).
[0036] The piggyBac transposon is a class 2 transposon that, although originally isolated from Trichoplusia ni (cabbage looper moth), has been shown to actively transpose in mammalian cells and to preferentially select available chromatin structures (Li et al., Molecular and Cellular Biology 33(7):1317-1330, 2013; Yoshida et al., Scientific Reports Article No. 43613 (2017)). The piggyBac transposon system is a useful tool for genetic manipulation in mammalian cells due to its ability to introduce foreign DNA into the genome and promote stable transgene expression. It has been used to facilitate stable transfection of mammalian cells, to generate stable and high-yielding polyclonal cultures of mammalian cells, to rapidly produce recombinant proteins from heterogeneous populations of transfected cells, and to cultivate clones for cell line development, as its recognition motifs are generally associated with regions of open chromatin and actively transcribed regions (published U.S. patent application number: US 2010 / 0311116; Ding et al., Cell 122(3):473-483, 2005; Wu et al., Proc. Natl. Acad. Sci. USA 103(4):15008-13, 2006; Matasci et al., Biotechnology & Bioengineering 108(9):2141-50, 2011; Matasci et al., BMC Proceedings [British Medical Council Journal] 5(SUPPL.8)p.34, 2011; Balasubramanian et al., J. Biotechnology [Journal of Biotechnology] 200:61-9, 2015; Balasubramanian et al., Biotechnology Progress [Biotechnology Progress] 32(5):1308-1317, 2016; Balasubramanian et al., Biotechnology & Bioengineering [Biotechnology & Bioengineering] 113(6):1234-43, 2016; Ahmadi et al., PLoS ONE [Public Library of Science One] 12(6):e0179902, 2017; Rajendra et al., Biotechnology Progress [Biotechnology Progress] 33(2):534-540, 2017; and Rajendra et al., Biotechnology Progress[Biotechnology Progress] 33(6):1436-1448,2017.).
[0037] Efforts to improve piggyBac efficiency on a molar basis have been made by modifying transposases to increase excision frequency using display library approaches and / or sequence comparison with homologous chromosomes from other species and generating hyperactive transposases (e.g., see U.S. Pat. No. 8,399,643; U.S. Pat. No. 9,670,503; U.S. Pat. No. 9,783,790; U.S. Pat. No. 9,546,382; and Yusa et al., Proc. Natl. Acad. Sci. USA 108(4):1531-36, 2011).
[0038] Little is known about the structure of piggyBac transposase. Analysis of the amino acid sequence of piggyBac transposase suggests that it is primarily an alpha-helical protein. In an attempt to improve the stability of piggyBac transposase introduced into cells, mutations were made within the alpha-helix and the putative N-linked glycosylation site (i.e., the NXS / t motif) and found to improve titer as described herein. Engineered versions of piggyBac transposase (including single mutations or combinations of multiple mutations) were transfected into cells along with a protein of interest (flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon), and expression of the protein of interest was evaluated compared to similar cells transfected with wild-type, unmutated piggyBac transposase from Trichoplusia ni (SEQ ID NO: 2) and cells that did not contain piggyBac transposase. It was found that a piggyBac transposase encoded by a nucleic acid sequence engineered for increased stability improved the titer of recombinant proteins expressed in cells comprising the engineered piggyBac transposase compared to the titer of recombinant proteins expressed in cells comprising wild-type piggyBac transposase or without piggyBac transposase.
[0039] As used herein, the term "piggyBac transposon" or "piggyBac transposable element" refers to a polynucleotide sequence that can be excised from a donor polynucleotide (e.g., a vector) and integrated into a target site (e.g., the genome or extrachromosomal DNA of a cell). For example, the piggyBac transposable element from Trichoplusia ni is 2472 bp in length, has short inverted repeats, includes an asymmetric terminal repeat structure, a 3-bp spacer between the 5'13-bp terminal repeat and the 5'19-bp internal repeat, and a 31-bp spacer between the 3'13-bp terminal repeat and the 3'19-bp internal repeat, and a single 2.1-kp open reading frame encoding a functional transposase. (Li et al., Mol. Genet. Genomics (2001) 266: 190-198; Cary et al., Virology (1989) 172: 156-169).
[0040] As used herein, the 5' and 3' inverted repeat elements of the piggyBac transposon refer to the 5' and 3' segments of T, including the target TTAA site, the terminal repeat spacer and internal repeat sequences of the piggyBac transposon, and for Trichoplusia ni, these include the target TTAA site, the 5' 13-bp terminal repeat sequence and the 5' 19-bp internal repeat sequence with a 3-bp spacer in between, and the 3' 13-bp terminal repeat sequence and the 3' 19-bp internal repeat sequence with a 31-bp spacer in between.
[0041] As used herein, the term "piggyBac transposase" refers to a polypeptide that catalyzes the excision of a piggyBac transposon from a donor polynucleotide (e.g., a vector) and the subsequent integration of the piggyBac transposon into the genome or extrachromosomal DNA of a target cell. The piggyBac transposase utilizes a cut and paste mechanism to insert into a TTAA target site that is replicated upon insertion and precisely excised after insertion, restoring the donor site to its pre-transposon state. (Elick et al., Genetica [Genetics] 98:33-41, 1996. Fraser et al., Insect Mol. Biol. [Insect Molecular Biology] 5:141-151, 1996. Wang and Fraser, Insect Mol. Biol. [Insect Molecular Biology] 1:109-116, 1993). The piggyBac transposase can exist as a polypeptide. Alternatively, the piggyBac transposase can present a nucleic acid molecule comprising a coding sequence encoding the piggyBac transposase. In some embodiments of the present invention, when the piggyBac transposase is present as an engineered nucleic acid molecule encoding the engineered piggyBac transposase, the engineered nucleic acid molecule can be present on the same vector comprising the piggyBac transposon, i.e., present in cis. In other embodiments of the present invention, the engineered nucleic acid molecule can be present on a second vector separate from the transposon, i.e., present in trans. The engineered piggyBac transposases described herein are unique in that the titer of the recombinant protein of interest expressed by cells comprising the engineered piggyBac transposase is improved compared to the titer of the recombinant protein of interest expressed by cells comprising the engineered piggyBac transposase or without the piggyBac transposase.
[0042] The terms "polypeptide" or "protein" are used interchangeably throughout and refer to molecules comprising two or more amino acid residues linked to each other by peptide bonds. Polypeptides and proteins also include macromolecules having one or more deletions, insertions, and / or substitutions of amino acid residues of the native sequence, i.e., polypeptides or proteins produced by naturally occurring non-recombinant cells; or molecules produced by genetically engineered cells or recombinant cells and comprising one or more deletions, insertions, and / or substitutions of amino acid residues of the amino acid sequence of a native protein. Polypeptides and proteins also include amino acid polymers in which one or more amino acids are chemical analogs of the corresponding naturally occurring amino acids and polymers. Polypeptides and proteins also include modifications including, but not limited to, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation, and ADP-ribosylation.
[0043] The piggyBac transposases described herein are intended to include polypeptides having insertions, deletions, or substitutions of one or more amino acid residues, or any combination thereof, as well as modifications other than insertions, deletions, or substitutions of amino acid residues, compared to wild-type Trichoplusia ni (cabbage looper moth) piggyBac transposase (SEQ ID NO: 2). As used herein, "amino acid substitution at one or more positions" means substitutions at 1, 2, 3, 4, 5, 6, or 7 of the positions described. In some embodiments, "amino acid substitution at one or more positions" means substitutions at 1, 2, 3, 4, 5, or 6 of the positions described. In some embodiments, "amino acid substitution at one or more positions" means substitutions at 1, 2, 3, 4, or 5 of the positions described. In some embodiments, "amino acid substitution at one or more positions" means substitutions at 1, 2, 3, 4, or 4 of the positions described. In some embodiments, "amino acid substitution at one or more positions" means substitutions at 1, 2, 3, or 4 of the positions described. In some embodiments, "amino acid substitution at one or more positions" means substitutions at 1, 2, or 3 of the positions described. In some embodiments, "amino acid substitution at one or more positions" means substitutions at 1 or 2 of the positions described.
[0044] The present invention provides a piggyBac transposase comprising an amino acid substitution at one or more of positions 147, 176, 221, 247, 429, 533, and 573 of SEQ ID NO: 2. In one embodiment, the transposase comprises an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO: 2. In one embodiment, the transposase comprises an amino acid substitution of threonine for serine at one or more of positions 429, 533, and 573 of SEQ ID NO: 2. In one embodiment, the transposase comprises an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO: 2, and / or a amino acid substitution of threonine for serine at one or more of positions 429, 533, and 573 of SEQ ID NO: 2. In related embodiments, the transposase comprises at least one of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO: 2. In related embodiments, the transposase comprises at least two of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO: 2. In another related embodiment, the transposase comprises a substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, a substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and a substitution of threonine for serine at position 533 of SEQ ID NO: 2. In one embodiment, the titer of the recombinant protein of interest expressed by cells transfected with the engineered piggyBac transposase is improved compared to the titer of the same protein of interest expressed by cells transfected with wild-type piggyBac transposase or without piggyBac transposase.
[0045] The present invention also provides a piggyBac transposase engineered to increase stability in a host cell, wherein the piggyBac transposase comprises an amino acid substitution at one or more of positions 147, 176, 221, 247, 429, 533, and 573 of SEQ ID NO: 2. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, or SEQ ID NO: 8. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 12. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 4. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 6. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 8. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 10. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 12. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 14. In another aspect, the present invention provides a piggyBac transposase having the amino acid sequence of SEQ ID NO:16.
[0046] Table 1 Amino acid sequences of wild-type and mutant piggyBac transposases
[0047]
[0048]
[0049]
[0050]
[0051]
[0052] The terms "polynucleotide," "nucleic acid molecule," or "engineered nucleic acid molecule" are used interchangeably throughout and include single-stranded and double-stranded nucleic acids, and include genomic DNA, RNA, mRNA, cDNA, or some combination of synthetic origin or unrelated to sequences normally found in nature. The terms "isolated polynucleotide," "isolated nucleic acid molecule," or "isolated engineered nucleic acid molecule" specifically refer to sequences of synthetic origin or sequences not normally found in nature. An isolated nucleic acid molecule comprising a specified sequence may include, in addition to the specified sequence, coding sequences for up to ten or even up to twenty other proteins or portions thereof, or may include operably linked regulatory sequences that control the expression of the coding region of the recited nucleic acid sequence, and / or may include vector sequences. The nucleotides comprising these nucleic acid molecules may be ribonucleotides or deoxyribonucleotides or modified forms of either type of nucleotide. These modifications include base modifications such as bromouridine and inosine derivatives; ribose modifications such as 2',3'-dideoxyribose; and internucleotide linkage modifications such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, anilinothioate, phosphoroanilide, and phosphoramidate.
[0053] As used herein, the term "isolated" means (i) free from at least some proteins or polynucleotides with which it is normally found, (ii) substantially free from other proteins or polynucleotides from the same source, e.g., from the same species, (iii) separated from at least about 50% of the polynucleotides, lipids, carbohydrates, or other materials with which it is associated in nature, (iv) operably associated (by covalent or non-covalent interactions) with polypeptides with which it is not associated in nature, or (v) not found in nature.
[0054] In one embodiment, the present invention provides an engineered nucleic acid molecule encoding a piggyBac transposase as described herein. The present invention also provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, or SEQ ID NO:18. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:9 or SEQ ID NO:11. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:17 or SEQ ID NO:18. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:5. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:7. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:9. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:11. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:13. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:15. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:17. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:18.
[0055] Table 2. Nucleic acid sequences of wild-type and mutant piggyBac transposases
[0056]
[0057]
[0058]
[0059]
[0060]
[0061]
[0062]
[0063]
[0064]
[0065]
[0066]
[0067]
[0068]
[0069]
[0070]
[0071] Target polypeptides and proteins may have scientific or commercial significance, including protein-based therapeutics. Target proteins include, in particular, secreted proteins, non-secreted proteins, intracellular proteins, or membrane-bound proteins. Target polypeptides and proteins can be produced by recombinant animal cell lines using cell culture methods and can be referred to as "recombinant proteins." The expressed (one or more) proteins can be produced intracellularly or secreted into a culture medium from which the protein can be recovered and / or collected. The term "isolated protein" or "isolated recombinant protein" refers to a target polypeptide or protein that has been purified from proteins or polypeptides or other contaminants that would interfere with its therapeutic, diagnostic, preventive, research, or other uses. Target proteins include proteins that exert therapeutic effects by binding to targets, particularly those listed below, including targets derived therefrom, targets associated therewith, and modifications thereof.
[0072] The target protein includes an "antigen binding protein". An "antigen binding protein" refers to a protein or polypeptide that includes an antigen binding region or antigen binding portion that has an affinity for another molecule (antigen) to which it binds. Antigen binding proteins encompass antibodies, peptibodies, antibody fragments, antibody derivatives, antibody analogs, fusion proteins (including single-chain variable fragments (scFv) and double-chain (bivalent) scFv, mutant proteins, and Xmabs). Also included are bispecific T cell engagers. Bispecific T cell engagers (e.g., HLE BiTEs, HeteroIg BITEs, and others), chimeric antigen receptors (CARs, CAR T), and T cell receptors (TCRs) with extensions (such as extended half-life).
[0073] scFv is a single-chain antibody fragment that has the variable regions of the heavy and light chains of an antibody linked together. See U.S. Patent Nos. 7,741,465 and 6,319,494 and Eshhar et al., Cancer Immunol Immunotherapy (1997) 45:131-136. scFv retains the ability of the parent antibody to specifically interact with the target antigen.
[0074] The term "antibody" includes glycosylated and non-glycosylated immunoglobulins of any isotype or subclass, or antigen binding regions thereof that compete with intact antibodies for specific binding. Unless otherwise indicated, antibodies include human, humanized, chimeric, multispecific, monoclonal, polyclonal, heteroIgG, bispecific antibodies, and oligomers or antigen binding fragments thereof. Antibodies include IgG1 type, IgG2 type, IgG3 type, or IgG4 type. Proteins with antigen binding fragments or antigen binding regions are also included, such as Fab, Fab', F(ab')2, Fv, diabodies, Fd, dAb, maxibodies, single-chain antibody molecules, single domain V H H, complementarity determining region (CDR) fragments, scFv, diabodies, triabodies, tetrabodies and polypeptides comprising at least a portion of an immunoglobulin sufficient to bind a specific antigen to a target polypeptide.
[0075] Also included are human, humanized, and other antigen binding proteins, such as human and humanized antibodies, that do not produce a significant deleterious immune response when administered to humans.
[0076] Also included are modified proteins, such as proteins that are chemically modified by non-covalent bonds, covalent bonds, or both covalent and non-covalent bonds. Also included are proteins that further comprise one or more post-translational modifications, which can be made by cellular modification systems or modifications introduced ex vivo by enzymatic and / or chemical methods or otherwise.
[0077] The protein of interest may also include a recombinant fusion protein comprising, for example, a multimerization domain such as a leucine zipper, a coiled coil, the Fc portion of an immunoglobulin, etc. Also included are proteins comprising all or part of the amino acid sequence of a differentiation antigen (referred to as CD proteins) or its ligands, or proteins substantially similar to any of these.
[0078] In some embodiments, the protein of interest may include a colony stimulating factor, such as granulocyte colony stimulating factor (G-CSF). Such G-CSF agents include, but are not limited to (filgrastim) and (Pegfilgrastim). Also included are erythropoiesis-stimulating agents (ESAs), such as (Epoetin α), (darbepoetin alfa), (Epoetine delta), (methoxypolyethylene glycol-epoetin beta), MRK-2578, INS-22, (Epoetin ζ), (Epoetin beta), (Epoetin ζ), (epoetin alfa), epoetin alfa Hexal, (Epoetin α), (Epoetin theta), (Epoetin theta), (Epoetin theta), epoetin alpha, epoetin beta, epoetin zeta, epoetin theta and epoetin delta, epoetin omega, epoetin iota, tissue plasminogen activator, GLP-1 receptor agonist, and molecules of any of the foregoing or variants or analogs and biosimilars thereof.
[0079] In some embodiments, the protein of interest may include proteins that specifically bind to one or more CD proteins, HER receptor family proteins, cell adhesion molecules, growth factors, nerve growth factors, fibroblast growth factors, transforming growth factors (TGFs), insulin-like growth factors, osteoinductive factors, insulin and insulin-related proteins, coagulation and coagulation-related proteins, colony stimulating factors (CSFs), other blood and serum proteins, blood group antigens; receptors, receptor-associated proteins, growth hormones, growth hormone receptors, T cell receptors; neurotrophic factors, neurotrophins, relaxins, interferons, interleukins, viral antigens, lipoproteins, integrins, rheumatoid factors, immunotoxins, surface membrane proteins, transporters, homing receptors, addressins, regulatory proteins, and immunoadhesins.
[0080] In some embodiments, the protein of interest binds to one or more of the following proteins, alone or in any combination: CD proteins (including but not limited to CD3, CD4, CD5, CD7, CD8, CD19, CD20, CD22, CD25, CD30, CD33, CD34, CD38, CD40, CD70, CD123, CD133, CD138, CD171, and CD174), HER receptor family proteins (including, for example, HER2, HER3, HER4, and EGF receptor), EGFRvIII, cell adhesion molecules (e.g., LFA-1, Mol, p150,95, VLA-4, ICAM-1, VCAM, and αv / β3 integrin), growth factors (including but not limited to, for example, vascular endothelial growth factor ("VEGF")); VEGFR2, growth hormone, thyroid stimulating hormone, follicle stimulating hormone, luteinizing hormone, growth hormone releasing factor, parathyroid hormone, mullerian-inhibiting substance (Müllerian-inhibiting substance), ovarian follicle stimulating hormone, luteinizing hormone, growth hormone releasing factor, parathyroid hormone, Müllerian-inhibiting substance, ...luteinizing hormone, growth hormone releasing factor, parathyroid hormone, luteinizing hormone, growth hormone releasing factor, parathyroid hormone, luteinizing hormone, growth hormone releasing factor, parathyroid hormone, luteinizing hormone, growth hormone releasing factor, parathyroid hormone, luteinizing hormone, growth hormone releasing factor, parathyroid hormone, luteinizing hormone, growth hormone releasing factor, luteinizing hormone, growth hormone releasing factor, parathyroid hormone, luteinizing hormone, growth hormone releasing factor, luteinizing hormone, substance), human macrophage inflammatory protein (MIP-1-α), erythropoietin (EPO), nerve growth factor (such as NGF-β), platelet-derived growth factor (PDGF), fibroblast growth factor (including, for example, aFGF and bFGF), epidermal growth factor (EGF), Cripto, transforming growth factor (TGF) (including TGF-α and TGF-β (including TGF-β1, TGF-β2, TGF-β3, TGF-β4 or TGF-β5)), insulin-like growth factor-I and insulin-like growth factor-II (IGF-I and IGF-II), des(1-3)-IGF-I (brain IGF-I) and osteoinductive factor, insulin and insulin-related proteins (including but not limited to insulin, insulin A chain, insulin B chain, proinsulin and insulin-like growth factor binding protein); (coagulation proteins and coagulation-related proteins, such as, in particular, factor VIII, tissue factor, von Willebrand factor (von Willebrand factor)). Willebrand factor, protein C, alpha-1-antitrypsin, plasminogen activators (such as urokinase and tissue plasminogen activator ("t-PA")), bombazine, thrombin, thrombopoietin and thrombopoietin receptors, colony-stimulating factors (CSFs) (including, among others, the following: M-CSF, GM-CSF, and G-CSF), other blood and serum proteins (including, but not limited to, albumin, IgE, and blood group antigens), receptors and receptor-associated proteins (including, for example, flk2 / flt3 receptors, obesity (OB) receptors, growth hormone receptors, and T-cell receptors);Neurotrophic factors, including but not limited to bone-derived neurotrophic factor (BDNF) and neurotrophin-3, neurotrophin-4, neurotrophin-5, or neurotrophin-6 (NT-3, NT-4, NT-5, or NT-6); relaxin A chain, relaxin B chain, and prorelaxin, interferons (including, for example, interferon alpha, interferon beta, and interferon gamma), interleukins (ILs) (e.g., IL-1 to IL-10, IL-12, IL-15, IL-17, IL-23, IL-12 / IL-23, IL-2Ra, IL1-R1, IL-6 receptor, IL-4 receptor, and / or IL-13 receptor, IL-13RA2, or IL-17 receptor, IL-1RAP;Viral antigens, including but not limited to AIDS envelope virus antigens, lipoproteins, calcitonin, glucagon, atrial natriuretic peptide, pulmonary surfactant, tumor necrosis factor-α and tumor necrosis factor-β, enkephalinase, BCMA, IgKappa, ROR-1, ERBB2, mesothelin, RANTES (normal T cell expressed and secreted factor regulated by activation), mouse gonadotropin-related peptide, DNA enzyme, FR-α, inhibin and activin, integrin, protein A or D, rheumatoid factor, immunotoxin, bone morphogenetic protein (BMP), superoxide dismutase, surface membrane protein, decay accelerating factor (DAF), AIDS envelope, transporter, homing receptor, MIC (MIC-a, MIC-B), ULBP 1-6, EPCAM, addressin, regulatory protein, immunoadhesin, antigen binding protein, growth hormone, CTGF, CTLA4, eotaxin-1, MUC1, CEA, c-MET, claudin-18, GPC-3, EPHA2, FPA, LMP1, MG7, NY-ESO-1, PSCA, ganglioside GD2, ganglioside GM2, BAFF, OPGL (RANKL), myostatin, Dickkopf-1 (DKK-1), An g2, NGF, IGF-1 receptor, hepatocyte growth factor (HGF), TRAIL-R2, c-Kit, B7RP-1, PSMA, NKG2D-1, programmed cell death protein 1 and ligand, PD1 and PDL1, mannose receptor / hCGβ, hepatitis C virus, mesothelin dsFv [PE38 conjugate, Legionella pneumophila (lly), IFNγ, interferon-gamma inducible protein 10 (IP10), IFNAR, TALL-1, thymic stromal lymphopoietin (TSLP), proprotein convertase subtilisin / Kexin PCSK9, stem cell factor, Flt-3, calcitonin gene-related peptide (CGRP), OX40L, α4β7, platelet-specific (platelet glycoprotein Iib / IIIb (PAC-1), transforming growth factor beta (TFGβ), zona pellucida sperm-binding protein 3 (ZP-3), TWEAK, platelet-derived growth factor receptor alpha (PDGFRα), sclerostin, and biologically active fragments or variants of any of the foregoing.
[0081] In another embodiment, the protein of interest comprises abciximab, adalimumab, adelimumab, aflibercept, alemtuzumab, alirocumab, anakinra, atacicept, basiliximab, belimumab, bevacizumab, biosozumab, blinatumomab, brentuximab, brodalumab, mocantuzumab, canakinumab, cetuximab, certolizumab pegol, canakinumab, daclizumab, Antibodies, denosumab, eculizumab, edrecolomab, efalizumab, epratuzumab, etanercept, evolocumab, galiximab, ganitazumab, gemtuzumab, golimumab, ibritumomab tiuxetan, infliximab, ipilimumab, leridizumab, ruximab, lxdkizumab, mapatumumab, motesanib phosphate diphosphate), muromonab-CD3, natalizumab, nesiritide, nimotuzumab, nivolumab, ocrelizumab, ofatumumab, omalizumab, oprelleukin, palivizumab, panitumumab, pembrolizumab, pertuzumab, pexelizumab, ranibizumab, rilotumumab, rituximab, romiplostim, lomosozumab, sargramostim, tocilizumab, tositumomab, trastuzumab, ustekinumab, vedolizumab, visilizumab, volocizumab, zalumab, zalutumumab, and biosimilars of any of the foregoing.
[0082] All foregoing are encompassed by protein of interest according to the present invention, and further include antibodies comprising 1,2,3,4,5 or 6 complementary determining regions (CDRs) of any of the above-mentioned antibodies. Such variants are also included, comprising a district of an amino acid sequence having 70% or higher, particularly 80% or higher, more particularly 90% or higher, more particularly 95% or higher, specifically 97% or higher, more specifically 98% or higher, more specifically 99% or higher identity with the reference amino acid sequence of the protein of interest. Homogeneity in this respect can be determined using multiple well-known and readily available amino acid sequence analysis software. Preferred software includes those software implementing Smith-Waterman (Smith-Waterman) algorithm, which is considered to the satisfactory solution to search and alignment sequence problems. Other algorithms can also be adopted, particularly when speed is an important consideration. Common programs for alignment and homology matching of DNA, RNA, and polypeptides that can be used in this regard include FASTA, TFASTA, BLASTN, BLASTP, BLASTX, TBLASTN, PROSRCH, BLAZE, and MPSRCH, the latter being an implementation of the Smith-Waterman algorithm for execution on massively parallel processors manufactured by MasPar.
[0083] Target protein can also include genetically engineered receptors, such as chimeric antigen receptors (CAR or CAR-T) and T cell receptors (TCR), and other proteins comprising antigen binding molecules that interact with the target antigen.By incorporating antigen binding molecules that interact with the target antigen, CAR can be engineered to bind antigens (such as cell surface antigens).CAR typically connects antigen binding domains (such as scFv) with one or more costimulatory ("signaling") domains and one or more activation domains in series.
[0084] Preferably, the antigen binding molecule is an antibody fragment thereof, and more preferably one or more single-chain antibody fragments ("scFv"). scFv is preferably used in chimeric antigen receptors because they can be engineered to be expressed as part of a single chain with other CAR components. See Krause et al., J. Exp. Med., [Journal of Experimental Medicine] 188 (4): 619-626, 1998; Finney et al., Journal of Immunology [Journal of Immunology], 161: 2791-2797, 1998.
[0085] Chimeric antigen receptors incorporate one or more costimulatory (signaling) domains to increase their effectiveness. See U.S. Patent Nos. 7,741,465 and 6,319,494, and Krause et al. and Finney et al. (supra), Song et al., Blood 119:696-706 (2012); Kalos et al., Sci Transl. Med. 3:95 (2011); Porter et al., N. Engl. J. Med. 365:725-33 (2011), and Gross et al., Annu. Rev. Pharmacol. Toxicol. 56:59-83 (2016).Suitable costimulatory domains can be derived from, among other sources, CD28, CD28T, OX40, 4-1BB / CD137, CD2, CD3 (α, β, δ, ε, γ, ξ), CD4, CD5, CD7, CD8, CD9, CD16, CD22, CD27, CD30, CD33, CD37, CD40, CD45, CD64, CD80, CD86, CD134, CD137, CD154, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1 (CD11a / CD18), CD247, CD276 (B7-H3), LIGHT (tumor necrosis factor superfamily member 14; TNFSF14), NKG2C, Igα (CD79a), DAP-10, Fcγ receptors, MHC Class I molecules, TNF, TNFr, integrin, signaling lymphocyte activation molecules, BTLA, Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8α, CD8β, IL-2Rβ, IL-2Rγ, IL-7Rα, ITGA4, VLA1, CD49a, ITGA4, IA4, C D49D, ITGA6, VLA-6, CD49f, ITGAD, CDl-ld, ITGAE, CD103, ITGAL, CDl-la, LFA-1, ITGAM, CDl-lb, ITGAX, CDl-lc, ITGBl, CD29, IT GB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE / RANKL, DNAM1(CD226), SLAMF4(CD244, 2B4), CD84, CD96(Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, 41-BB, GADS, SLP-76, PAG / Cbp, CD19a, CD83 ligand, or a fragment or combination thereof. The co-stimulatory domain may comprise one or more of an extracellular portion, a transmembrane portion, and an intracellular portion.
[0086] CARs also include one or more activation domains. CD3ζ is a component of the T cell receptor on natural T cells and has been shown to be an important intracellular activation element within CARs.
[0087] CAR is a transmembrane protein that includes an extracellular domain, typically an antigen binding protein that can recognize and bind to the antigen of interest, and also includes a "hinge" region. In addition, there is a transmembrane domain and an intracellular (cytoplasmic) domain.
[0088] The extracellular domain is conducive to signal transduction and the effective response of lymphocytes to antigens. From any protein described herein or any combination thereof. The extracellular domain can be derived from a synthetic or natural source, such as a protein described herein. The extracellular domain generally includes a hinge portion. This is a part of the extracellular domain, sometimes referred to as a "spacer" region. The hinge can be derived from these proteins as described herein, particularly the above-mentioned costimulatory proteins, and immunoglobulin (Ig) sequences or other suitable molecules to achieve the special distance required from the target cell.
[0089] The transmembrane domain can be fused to the extracellular domain of the CAR. It can similarly be fused to the intracellular domain of the CAR. The transmembrane domain can be derived from a synthetic or natural source, such as a protein described herein, particularly the above-mentioned costimulatory proteins.
[0090] The intracellular (cytoplasmic) domain can be fused to the transmembrane domain and can provide activation of at least one of the normal effector functions of the immune cell. The effector function of the T cell can be, for example, a cytolytic activity or an adjuvant activity including the secretion of cytokines. The intracellular domain can be derived from a protein as described herein, in particular derived from CD3.
[0091] The polynucleotides, polypeptides, vectors, host cells, immune cells, compositions, etc. according to the present invention can be prepared using various known techniques.
[0092] Also provided herein are expression systems and constructs in the form of plasmids, expression vectors, transcription cassettes or expression cassettes comprising at least one nucleic acid molecule as described above, and host cells comprising these expression systems or constructs. As used herein, "carrier" means any molecule or entity (for example, nucleic acid, plasmid, phage, transposon, clay, chromosome, virus, viral capsid, virion, naked DNA, composite DNA, etc.) suitable for transferring and / or transporting information coding proteins to a host cell and / or a specific location and / or a compartment within a host cell. Carriers can include viral and non-viral vectors, non-additional mammalian vectors. Carriers are commonly referred to as expression vectors, for example, recombinant expression vectors and cloning vectors. Carriers can be introduced into host cells to allow replication of the carrier itself, and thereby increase the copy of the polynucleotides contained therein. Cloning vectors can contain sequence components, which generally include but are not limited to replication origin, promoter sequence, transcription initiation sequence, enhancer sequence and selective marker. These elements can be suitably selected by those of ordinary skill in the art.
[0093] A vector is a vector that can be used to transform a host cell and contains a nucleic acid sequence that directs and / or controls (along with the host cell) the expression of one or more heterologous coding regions operably linked thereto. An expression construct may include, but is not limited to, sequences that affect or control transcription, translation, and, when introns are present, RNA splicing of the coding region operably linked thereto. "Operably linked" means that the components to which the term is applied are in a relationship that allows them to perform their inherent functions. For example, the arrangement of a control sequence (e.g., a promoter) in a vector that is "operably linked" to a protein coding sequence is such that normal activity of the control sequence results in transcription of the protein coding sequence, thereby resulting in recombinant expression of the encoded protein.
[0094] The vector can be selected to be functional in the particular host cell being employed (i.e., the vector is compatible with the host cell machinery, thereby allowing amplification and / or expression of the gene to occur). In some embodiments, the vector used employs a protein fragment complementation assay using a protein reporter sequence such as dihydrofolate reductase (see, e.g., U.S. Patent No. 6,270,964). Suitable expression vectors are known in the art and are also commercially available.
[0095] Typically, vectors used in any host cell will contain sequences for plasmid maintenance and for cloning and expressing exogenous nucleotide sequences. Such sequences will typically include one or more of the following nucleotide sequences: a promoter, one or more enhancer sequences, an origin of replication, transcriptional and translational control sequences, a transcriptional termination sequence, a complete intron sequence containing donor and acceptor splice sites, various pre-sequences (pre-sequences / pro-sequences) to improve glycosylation or yield, a natural or heterologous signal sequence (leader sequence or signal peptide) for polypeptide secretion, a ribosome binding site, a polyadenylation sequence, an internal ribosome entry site (IRES) sequence, an expression enhancing sequence element (EASE), a tripartite leader sequence (TPA) and VA gene RNA from adenovirus 2, a polylinker region for inserting a polynucleotide encoding the polypeptide to be expressed, and a selectable marker element. Vectors can be constructed from starting vectors (such as commercially available vectors), and other elements can be obtained separately and ligated into the vector. Methods for obtaining each component are well known to those skilled in the art.
[0096] Vector components can be homologous (i.e., from the same species and / or strain as the host cell), heterologous (i.e., from a species other than the host cell species or strain), hybrid (i.e., a combination of flanking sequences from more than one source), synthetic, or natural. The sequences of useful components in these vectors can be obtained by methods well known in the art, such as those previously identified by mapping and / or by restriction endonucleases. Alternatively, they can be obtained by polymerase chain reaction (PCR) and / or by screening genomic libraries with appropriate probes.
[0097] A ribosome binding site is usually necessary for initiation of mRNA translation and is characterized by a Shine-Dalgarno sequence (prokaryotes) or a Kozak sequence (eukaryotes). This element is typically located 3' of the promoter and 5' of the coding sequence of the polypeptide to be expressed.
[0098] Origins of replication facilitate amplification of the vector in the host cell. They can be included as part of commercially available prokaryotic vectors or chemically synthesized based on known sequences and ligated into the vector. Various viral sources (e.g., SV40, polyoma virus, adenovirus, vesicular stomatitis virus (VSV), or papillomaviruses (such as HPV or BPV)) can be used to clone vectors in mammalian cells.
[0099] The transcription and translation control sequences of mammalian host cell expression vectors can be excised from the viral genome. Commonly used promoter and enhancer sequences are derived from polyoma virus, adenovirus 2, simian virus 40 (SV40) and human cytomegalovirus (CMV). For example, the human CMV promoter / enhancer of immediate early gene 1 can be used. See, for example, Patterson et al. (1994), Applied Microbiol.Biotechnol. [Applied Microbiology and Biotechnology] 40:691-98. DNA sequences derived from the SV40 viral genome, for example, SV40 sources, early and late promoters, enhancers, splicing sequences and polyadenylation sites can be used to provide other genetic elements for expressing structural gene sequences in mammalian host cells. Viral early and late promoters are particularly useful because they are readily available as fragments from the viral genome and can also contain the viral origin of replication (Fiers et al., (1978), Nature 273:113; Kaufman (1990), Meth. in Enzymol. 185:487-511). Smaller or larger SV40 fragments can also be used, provided that the approximately 250 bp stretch from the Hind III site to the Bgl I site located in the SV40 viral origin of replication is included.
[0100] The transcription termination sequence is typically located at the 3' end of the polypeptide coding region and is used to terminate transcription. Typically, the transcription termination sequence in prokaryotes is a GC-rich fragment followed by a poly-T sequence. Although the sequence can be easily cloned from a library or even purchased commercially as part of a vector, it can also be easily synthesized using those nucleic acid synthesis methods known to those skilled in the art.
[0101] Selectable marker genes encode proteins necessary for the survival and growth of host cells grown in selective media. Typical selectable marker genes encode proteins that (a) confer resistance to antibiotics or other toxins (e.g., ampicillin, tetracycline, or kanamycin for prokaryotic host cells); (b) supplement nutritional deficiencies of the cells; or (c) provide important nutrients that are not available from complex or defined media. Specific selectable markers are kanamycin resistance genes, ampicillin resistance genes, and tetracycline resistance genes. Advantageously, the neomycin resistance gene can also be used for selection in prokaryotic and eukaryotic host cells.
[0102] Other selectable genes can be used to amplify the genes to be expressed. Amplification is a process in which genes required for the production of proteins important for growth or cell survival are repeated in tandem within the chromosomes of successive generations of recombinant cells. Examples of suitable selective markers for mammalian cells include the glutamine synthase (GS) / methionine sulfoximine (MSX) system, dihydrofolate reductase (DHFR), and promoterless thymidine kinase genes. Mammalian cell transformants are placed under selective pressure, wherein, due to the presence of selectable genes in the vector, only transformants are uniquely suited for survival. By culturing transformed cells under conditions of continuously increasing the concentration of the selector in the culture medium, selective pressure is applied by amplifying the selectable gene and the DNA encoding the target protein. Thus, an increased amount of target polypeptide is synthesized by the amplified DNA.
[0103] In some cases, such as when glycosylation is desired in a eukaryotic host cell expression system, various presequences or presequences can be manipulated to improve glycosylation or yield. For example, the peptidase cleavage site of a particular signal peptide can be changed, or a presequence that can also affect glycosylation can be added. The final protein product may have one or more additional amino acids at position -1 (relative to the first amino acid of the mature protein) that are easy to express, and these amino acids may not be completely removed. For example, the final protein product may have one or two amino acid residues found in the peptidase cleavage site attached to the amino terminus. Alternatively, if the enzyme cuts at the enzyme cleavage site region within the mature polypeptide, the use of some enzyme cleavage sites can produce a slightly truncated form of the desired polypeptide.
[0104] Expression and cloning typically contain a promoter that is recognized by the host organism and operably connected to the molecule encoding the target protein. A promoter is a non-transcribed sequence located upstream (i.e., 5') of the start codon of a structural gene (generally within about 100 to 1000 bp) that controls transcription of the structural gene. Promoters are generally grouped into two categories: inducible promoters and constitutive promoters. Inducible promoters initiate transcription of the DNA under their control at an increased level in response to a certain change in culture conditions (such as the presence or absence of nutrients, or temperature changes). On the other hand, constitutive promoters consistently transcribe the gene to which they are operably connected, i.e., have minimal control or no control over gene expression. Many promoters recognized by a variety of potential host cells are well known.
[0105] Suitable promoters for yeast hosts are also well known in the art. Yeast enhancers are preferably used with yeast promoters. Suitable promoters for mammalian host cells are well known and include, but are not limited to, those obtained from viral genomes such as polyoma virus, transmissible epithelioma virus, adenovirus (such as adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, retrovirus, hepatitis B virus, and simian virus 40 (SV40). Other suitable mammalian promoters include heterologous mammalian promoters, such as heat shock promoters and actin promoters.
[0106] Other promoters that may be of interest include, but are not limited to, the SV40 early promoter (Benoist and Chambon, 1981, Nature 290:304-310); the CMV promoter (Thornsen et al., 1984, Proc. Natl. Acad. USA 81:659-663); the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., 1980, Cell 22:787-797); the herpes virus thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. USA [Proc. Natl. Acad. Sci. USA] 75:3727-3731); or the tac promoter (DeBoer et al., 1983, Proc. Natl. Acad. Sci. USA 80:21-25).Also of interest are the following animal transcriptional control regions, which exhibit tissue specificity and have been used in transgenic animals: the elastase I gene control region, which is active in pancreatic acinar cells (Swift et al., 1984, Cell 38:639-646; Ornitz et al., 1986, Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, 1987, Hepatology 7:425-515); the insulin gene control region, which is active in pancreatic β cells (Hanahan, 1985, Nature 315:115-122); the immunoglobulin gene control region, which is active in lymphoid cells (Grosschedl et al., 1984, Cell 38:647-658); Adames et al., 1985, Nature 318:533-538; Alexander et al., 1987, Mol. Cell. Biol. 7:1436-1444); a mouse mammary tumor virus control region active in testicular, mammary, lymphoid, and mast cells (Leder et al., 1986, Cell 45:485-495); an albumin gene control region active in the liver (Pinkert et al., 1987, Genes Biol. 7:1436-1444); and Devel. [Genes and Development] 1:268-276); the alpha-fetoprotein gene control region active in the liver (Krumlauf et al., 1985, Mol. Cell. Biol. [Molecular Cell Biology] 5:1639-1648; Hammer et al., 1987, Science [Science] 253:53-58); the alpha-1-antitrypsin gene control region active in the liver (Kelsey et al., 1987, Gene ... and Devel. [Genes and Development] 1:161-171); the beta-globin gene control region, which is active in myeloid cells (Mogram et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94); the myelin basic protein gene control region, which is active in oligodendrocytes of the brain (Readhead et al., 1987, Cell 48:703-712); the myosin light chain-2 gene control region, which is active in skeletal muscle (Sani, 1985, Nature 314:283-286); and the gonadotropin-releasing hormone gene control region, which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378).
[0107] Enhancer sequences can be inserted into the vector to increase transcription of higher eukaryotic organisms. Enhancers are cis-acting elements of DNA, and are generally about 10-300bp in length, acting on promoters to increase transcription. Enhancers are relatively independent in direction and position and have been found in the 5' and 3' positions of the transcription unit. Several enhancer sequences (for example, globulin, elastase, albumin, α-fetoprotein and insulin) known to be available from mammalian genes are known. However, enhancers from viruses are typically used. SV40 enhancer, cytomegalovirus early promoter enhancer, polyoma enhancer and adenovirus enhancer as known in the art are exemplary reinforcing elements for activating eukaryotic promoters. Although enhancers can be positioned at 5' or 3' of the coding sequence in the vector, they are typically located at the site 5' of the promoter.
[0108] A sequence encoding an appropriate natural or heterologous signal sequence (leader sequence or signal peptide) can be incorporated into an expression vector to promote extracellular secretion of the target protein. The choice of signal peptide or leader sequence depends on the type of host cell in which the target protein is to be produced, and the heterologous signal sequence can replace the natural signal sequence. Examples of signal peptides that are functional in mammalian host cells include the following: the signal sequence of interleukin-7 described in U.S. Patent No. 4,965,195; the signal sequence of the interleukin-2 receptor described in Cosman et al., 1984, Nature [Nature] 312:768; the interleukin-4 receptor signal peptide described in European Patent No. 0367566; the type I interleukin-1 receptor signal peptide described in U.S. Patent No. 4,968,607; and the type II interleukin-1 receptor signal peptide described in European Patent No. 0460846.
[0109] Other control sequences shown to improve heterologous gene expression from mammalian expression vectors include elements such as the expression enhancing sequence element (EASE) derived from CHO cells (Morris et al., Animal Cell Technology, pp. 529-534 (1997); U.S. Pat. Nos. 6,312,951 Bl, 6,027,915, and 6,309,841 Bl) and the tripartite leader sequence (TPL) and VA gene RNA from adenovirus 2 (Gingeras et al. (1982), J. Biol. Chem. 257: 13475-13491). Internal ribosome entry site (IRES) sequences of viral origin enable efficient translation of bicistronic mRNAs (Oh and Sarnow (1993) Current Opinion in Genetics and Development 3:295-300; Ramesh et al. (1996) Nucleic Acids Research 24:2697-2700).
[0110] In one embodiment, the present invention provides a vector comprising a nucleic acid molecule encoding a piggyBac transposase as described herein. In one embodiment, the vector further comprises a piggyBac transposon comprising an insertion site for at least one exogenous nucleic acid sequence encoding at least one protein of interest. In one embodiment, the one or more exogenous nucleic acid molecules express multiple proteins of interest. In one embodiment, the vector comprises a bicistronic or polycistronic construct encoding multiple proteins of interest. In one embodiment, the transposon comprises at least the 5' and 3' inverted repeat elements of the piggyBac transposon. In one embodiment, an engineered nucleic acid molecule encoding a piggyBac transposase as described herein is provided. In one embodiment, a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, or SEQ ID NO:18 is provided. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:9 or SEQ ID NO:11. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:17 or SEQ ID NO:18. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:5. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:7. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:9. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 11. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 13. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 15.In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 17. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 18.
[0111] In one embodiment, a piggyBac transposase is provided, comprising an amino acid substitution at one or more of positions 147, 176, 221, 247, 429, 533, and 573 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of threonine for serine at one or more of positions 429, 533, and 573 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO: 2, and / or an amino acid substitution of threonine for serine at one or more of positions 429, 533, and 573 of SEQ ID NO: 2. In related embodiments, the piggyBac transposase comprises at least one of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO: 2. In related embodiments, the piggyBac transposase comprises at least two of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO: 2. In another related embodiment, the piggyBac transposase comprises a substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, a substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and a substitution of threonine for serine at position 533 of SEQ ID NO: 2. In one embodiment, a piggyBac transposase is provided, the piggyBac transposase having the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. In another aspect, the present invention provides a piggyBac transposase having the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, or SEQ ID NO: 8.In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 12. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 4. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 6. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 8. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 10. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 12. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 14. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 16.
[0112] In one embodiment, a single vector comprising a piggyBac transposase as described herein and a transposon comprising an insertion site for at least one exogenous nucleic acid sequence encoding at least one protein of interest can be transfected into a cell. In one embodiment, the present invention provides a nucleic acid molecule encoding a piggyBac transposase as described herein, further comprising at least one nucleic acid molecule encoding at least one protein of interest flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon. In one embodiment, the one or more exogenous nucleic acid molecules express multiple proteins of interest. In one embodiment, the vector comprises a bicistronic or multicistronic construct encoding multiple proteins of interest.
[0113] In another embodiment, the present invention provides a vector comprising an engineered nucleic acid molecule encoding a piggyBac transposase as described herein and a second vector comprising a piggyBac transposon comprising an insertion site for one or more exogenous nucleic acid molecules encoding at least one protein of interest, wherein the two vectors can be co-transfected into a cell. In a related embodiment, the transposon comprises at least the 5' and 3' inverted repeat elements of the piggyBac transposon. In one embodiment, the one or more exogenous nucleic acid molecules express multiple proteins of interest. In one embodiment, the vector comprises a bicistronic or multicistronic construct encoding multiple proteins of interest.
[0114] After construction, one or more vectors can be inserted into suitable cells to amplify and / or express polypeptides. The conversion of expression vectors to selected cells can be completed by well-known methods, including transfection, infection, calcium phosphate coprecipitation, electroporation, nuclear transfection, microinjection, DEAE-dextran-mediated transfection, cationic lipid-mediated delivery, liposome-mediated transfection, microprojectile bombardment, receptor-mediated gene delivery, polylysine, histone, chitosan and peptide-mediated delivery. The selected method will vary with the host cell type to be used. These methods and other suitable methods are well known to those skilled in the art and are described in manuals and other technical publications, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, [Molecular Cloning: Laboratory Manual], 3rd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (2001).
[0115] As used herein, the term "transformation" refers to a change in the genetic characteristics of a cell. When a cell is modified to contain new DNA or RNA, the cell is transformed. For example, a cell is genetically modified from its original state by the introduction of new genetic material via transfection, transduction, or other techniques. After transfection or transduction, the transforming DNA can be physically integrated into the cell chromosome and recombined with the cell's DNA, or it can be temporarily maintained as a free element that is not replicated, or it can replicate independently as a plasmid. When the transforming DNA replicates as the cell divides, the cell is considered to have been "stably transformed."
[0116] As used herein, the term "transfection" refers to the uptake of foreign or exogenous DNA by a cell. Many transfection techniques are well known in the art and are disclosed herein. See, for example, Graham et al., 1973, Virology 52:456; Sambrook et al., 2001, Molecular Cloning: A Laboratory Manual, supra; Davis et al., 1986, Basic Methods in Molecular Biology, Elsevier; Chu et al., 1981, Gene 13:197.
[0117] As used herein, the term "transduction" refers to the process by which foreign DNA is introduced into cells via a viral vector. See Jones et al. (1998). Genetics: principles and analysis. Boston: Jones & Bartlett Publ.
[0118] One or more "cells" include any prokaryotic or eukaryotic cells. The cell can be an in vitro cell, an in vitro cell, or an in vivo cell, and can be alone or as a part of a higher structure (such as a tissue or organ). Cells include "host cells," also referred to as "cell lines," which are genetically engineered to express polypeptides of commercial or scientific significance. Host cells are typically derived from lineages from primary cultures that can be maintained in culture for an unlimited time. Genetically engineered host cells involve transfection, transformation, or transduction of cells with recombinant polynucleotide molecules, and / or otherwise altered (e.g., by homologous recombination and gene activation or fusion of recombinant cells with non-recombinant cells) to cause the host cell to express the desired recombinant polypeptide. Methods and vectors for genetically engineering cells and / or cell lines to express a polypeptide of interest are well known to those skilled in the art; for example, various techniques are described in Current Protocols in Molecular Biology, ed. Ausubel et al. (Wiley & Sons, New York, 1990, and quarterly updates); Sambrook et al., Molecular Cloning: A Laboratory Manual (Cold Spring Laboratory Press, 1989); Kaufman, RJ, Large Scale Mammalian Cell Culture, 1990, pp. 15-69.
[0119] The host cell can be any prokaryotic cell (e.g., E. coli) or eukaryotic cell (e.g., yeast, insect, or animal cell (e.g., CHO cell)). Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. Prokaryotic host cells include eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as Escherichia, e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimurium, Serratia, such as Serratia marcescans, and Shigella, as well as Bacillus, e.g., B. subtilis and B. licheniformis, Pseudomonas, and Streptomyces. Saccharomyces cerevisiae or common baker's yeast is the most commonly used among the lower eukaryotic host microorganisms. However, many other genera, species and strains are generally available and useful herein, such as Pichia, e.g., P. pastoris, Schizosaccharomyces pombe; Kluyveromyces, Yarrowia; Candida; Trichoderma reesia; Neurospora crassa; Schwanniomyces, such as Schwanniomyces occidentalis; and filamentous fungi, such as Neurospora, Penicillium, Tolypocladium, and Aspergillus hosts, such as A. nidulans and A. niger.
[0120] Animal cell lines are derived from cells whose progenitor cells originate from multicellular animals. One type of animal cell line is a mammalian cell line. A variety of mammalian cell lines suitable for growth in culture are available from the American Type Culture Collection (Manassas, Virginia) and commercial suppliers. Examples of cell lines commonly used in the industry include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 cells or 293 cells subcloned for growth in suspension culture, (Graham et al., J. Gen Virol. 36:59, 1977); baby hamster kidney cells (BHK, ATCC CCL 10); mouse Sertoli cells (TM4, Mather, Biol. Reprod. 23:243-251, 1980); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); Buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human hepatoma cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals NY Acad. Sci. [Annals of the New York Academy of Sciences] 383:44-68, 1982); MRC 5 cells or FS4 cells; mammalian myeloma cells, as well as many other cell lines and Chinese hamster ovary (CHO) cells. CHO cells are widely used for the production of complex recombinant proteins. Dihydrofolate reductase (DHFR)-deficient mutant cell lines (Urlaub et al. (1980), Proc Natl Acad Sci USA [Proceedings of the National Academy of Sciences of the United States of America] 77:4216-4220) DXB11 and DG-44 are ideal CHO host cell lines because an efficient DHFR selectable and amplifiable gene expression system allows high-level expression of recombinant proteins in these cells (Kaufman et al., 1992). RJ (1990), Meth Enzymol 185:537-566). Also included are glutamine synthetase (GS)-knockout CHOK1SV cell lines using methionine sulfoximine (MSX) selection for glutamine synthetase (GS). Also included are CHOK1 cells (ATCC CCL61). Furthermore, these cells are easily manipulated as adherent or suspension cultures and exhibit relatively good genetic stability.CHO cells and proteins recombinantly expressed therein have been extensively characterized and have been approved for clinical commercial manufacturing by regulatory agencies.
[0121] Cells may also include monocytes, peripheral blood mononuclear cells, bone marrow-derived monocytes, cord blood-derived monocytes, lymphocytes, monocytes, dendritic cells, macrophages, T cells, naive T cells, memory T cells, CD28 + cells, CD4 + CD8 + cells, CD45RA + cells, CD45RO + Cells, natural killer cells, hematopoietic stem cells, pluripotent embryonic stem cells, induced pluripotent stem cells, or a combination thereof. In particular, these cells can be collected from a donor or a subject for the purpose of genetically modifying and reintroducing these cells into the donor or subject.
[0122] In one embodiment, cells are provided that are transfected with a piggyBac transposase encoded by a nucleic acid sequence as described herein. In one embodiment, the invention provides cells that are transfected with a piggyBac transposase encoded by a nucleic acid sequence as described herein. In one embodiment, the invention provides cells that are transfected with a vector comprising an engineered nucleic acid molecule encoding a piggyBac transposase as described herein. In one embodiment, the invention provides cells that are transfected with an engineered nucleic acid molecule encoding a piggyBac transposase as described herein and a vector comprising a nucleic acid molecule encoding a protein of interest, the protein of interest being flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon. In another embodiment, the invention provides cells that are co-transfected with a vector comprising an engineered nucleic acid molecule encoding a piggyBac transposase as described herein and a vector comprising a nucleic acid sequence encoding a protein of interest, the protein of interest being flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon. In one embodiment, the present invention provides cells transfected with a vector comprising an engineered nucleic acid molecule encoding a piggyBac transposase as described herein and a nucleic acid molecule encoding a protein of interest flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon. In a related embodiment, the cell is a cell line. In a related embodiment, the cell is a host cell. In a related embodiment, the cell is a CHO cell. In a related embodiment, the cell is an immune cell. In a related embodiment, the titer of the recombinant protein of interest expressed by cells transfected with the engineered piggyBac transposase is improved compared to the titer of the recombinant protein of interest expressed by cells transfected with wild-type piggyBac transposase or not transfected with piggyBac transposase. In one embodiment, an engineered nucleic acid molecule encoding a piggyBac transposase as described herein is provided. In one embodiment, a piggyBac transposase is provided that is encoded by the nucleic acid sequence of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 18. In another aspect, the present invention provides a piggyBac transposase that is encoded by the nucleic acid sequence of SEQ ID NO: 3, SEQ ID NO: 5, or SEQ ID NO: 7. In another aspect, the present invention provides a piggyBac transposase that is encoded by the nucleic acid sequence of SEQ ID NO: 11, SEQ ID NO: 13, or SEQ ID NO: 15.In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:9 or SEQ ID NO:11. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:17 or SEQ ID NO:18. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:5. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:7. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:9. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:11. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:13. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:15. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 17. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 18.
[0123] In one embodiment, a piggyBac transposase is provided, comprising an amino acid substitution at one or more of positions 147, 176, 221, 247, 429, 533, and 573 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of threonine for serine at one or more of positions 429, 533, and 573 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO: 2, and / or an amino acid substitution of threonine for serine at one or more of positions 429, 533, and 573 of SEQ ID NO: 2. In related embodiments, the piggyBac transposase comprises at least one of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO: 2. In related embodiments, the piggyBac transposase comprises at least two of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO: 2. In another related embodiment, the piggyBac transposase comprises a substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, a substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and a substitution of threonine for serine at position 533 of SEQ ID NO: 2. In one embodiment, a piggyBac transposase is provided, the piggyBac transposase having the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. In another aspect, the present invention provides a piggyBac transposase having the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, or SEQ ID NO: 8.In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 12. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 4. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 6. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 8. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 10. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 12. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 14. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 16.
[0124] In one embodiment, the present invention provides for engineering a nucleic acid molecule encoding a piggyBac transposase to increase its stability in a cell, and transfecting the cell with a vector comprising the engineered nucleic acid molecule encoding the engineered piggyBac transposase and a nucleic acid molecule encoding a protein of interest flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon, wherein the titer of the recombinant protein of interest expressed by cells transfected with the engineered piggyBac transposase is improved compared to the titer of the recombinant protein of interest expressed by cells transfected with wild-type piggyBac transposase or not transfected with the piggyBac transposase. In one embodiment, an engineered nucleic acid molecule encoding a piggyBac transposase as described herein is provided. In one embodiment, a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 18 is provided. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:9 or SEQ ID NO:11. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:17 or SEQ ID NO:18. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:5. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:7. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:9. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 11. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 13. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 15.In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 17. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 18.
[0125] In one embodiment, a piggyBac transposase is provided, comprising an amino acid substitution at one or more of positions 147, 176, 221, 247, 429, 533, and 573 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of threonine for serine at one or more of positions 429, 533, and 573 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO: 2, and / or an amino acid substitution of threonine for serine at one or more of positions 429, 533, and 573 of SEQ ID NO: 2. In related embodiments, the piggyBac transposase comprises at least one of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO: 2. In related embodiments, the piggyBac transposase comprises at least two of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO: 2. In another related embodiment, the piggyBac transposase comprises a substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, a substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and a substitution of threonine for serine at position 533 of SEQ ID NO: 2. In one embodiment, a piggyBac transposase is provided, the piggyBac transposase having the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. In another aspect, the present invention provides a piggyBac transposase having the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, or SEQ ID NO: 8.In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 12. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 4. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 6. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 8. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 10. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 12. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 14. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 16.
[0126] In one embodiment, the present invention provides for engineering a nucleic acid molecule encoding a piggyBac transposase to increase its stability in a cell, and transfecting the cell with a vector comprising the engineered nucleic acid molecule encoding the engineered piggyBac transposase and a vector comprising a nucleic acid molecule encoding a protein of interest flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon, wherein the titer of the recombinant protein of interest expressed by cells transfected with the engineered piggyBac transposase is improved compared to the titer of the recombinant protein of interest expressed by cells transfected with wild-type piggyBac transposase or not transfected with the piggyBac transposase.
[0127] Also provided are host cells transfected with a vector comprising a nucleic acid encoding a protein of interest and expressing the protein of interest when cultured under appropriate conditions. The expressed protein can then be collected from the culture medium (if the host cell secretes it into the culture medium) or directly from the host cell producing the protein (if it is not secreted). The selection of an appropriate host cell will depend on a variety of factors, such as the desired expression level, polypeptide modifications required or necessary for activity (such as glycosylation or phosphorylation), and the ease with which the protein can be folded into a biologically active molecule.
[0128] In one embodiment, the present invention provides a recombinant protein of interest expressed by cells transfected with a vector comprising an engineered nucleic acid molecule encoding a piggyBac transposase as described herein. In one embodiment, the present invention provides cells transfected with a vector comprising an engineered nucleic acid molecule encoding a piggyBac transposase as described herein, the vector further comprising a nucleic acid sequence encoding a protein of interest flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon. In one embodiment, the present invention provides a recombinant protein of interest expressed by cells co-transfected with a vector comprising an engineered nucleic acid molecule encoding a piggyBac transposase as described herein and a vector comprising a nucleic acid molecule encoding a protein of interest flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon.
[0129] In one embodiment, the present invention provides a pharmaceutical composition comprising a recombinant protein of interest expressed by a cellular host transfected with a vector comprising an engineered nucleic acid molecule encoding a piggyBac transposase as described herein. In one embodiment, the present invention provides a host cell transfected with a vector comprising an engineered nucleic acid molecule encoding a piggyBac transposase as described herein, the vector further comprising a nucleic acid sequence encoding a protein of interest, the protein of interest flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon. In one embodiment, the present invention provides a pharmaceutical composition comprising a recombinant protein of interest expressed by a host cell co-transfected with a vector comprising an engineered nucleic acid molecule encoding a piggyBac transposase as described herein and a vector comprising a nucleic acid molecule encoding a protein of interest, the protein of interest flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon.
[0130] "Culture" or "culturing" refers to the growth and propagation of cells outside a multicellular organism or tissue. Suitable culture conditions for mammalian cells are known in the art. Cell culture medium and tissue culture medium are used interchangeably to refer to a culture medium suitable for the growth of host cells during in vitro cell culture. Typically, a cell culture medium comprises a buffer, salts, an energy source, amino acids, vitamins, and trace amounts of essential elements. Any culture medium capable of supporting the growth of appropriate host cells in culture can be used. The cell culture medium can be further supplemented with other components to maximize cell growth, cell viability, and / or recombinant protein production in a particular cultured host cell, and such cell culture media are commercially available and include RPMI-1640 medium, RPMI-1641 medium, Dulbecco's Modified Eagle's Medium (DMEM), Eagle's Minimum Essential Medium, F-12K medium, Ham's F12 medium, Iscove's Modified Dulbecco's Medium, McCoy's 5A medium, Leibovitz's L-15 medium, and serum-free medium, such as EX-CELL TM The cell culture medium can be obtained from the American Type Culture Collection, SAFC Biosciences, and other suppliers. Cell culture media can be serum-free, protein-free, growth factor-free, and / or peptone-free. Cell cultures can also be enriched by adding nutrients and used at concentrations higher than their usual, recommended concentrations.
[0131] Various culture medium formulations can be used during the culture process, for example, to facilitate the transition from one stage (e.g., growth stage or growth phase) to another stage (e.g., production stage or production phase) and / or to optimize conditions during cell culture (e.g., concentrated culture medium provided during perfusion culture). Growth medium formulations can be used to promote cell growth and minimize protein expression. Production medium formulations can be used to promote the production of target protein and the maintenance of cells while minimizing the growth of new cells. Feed medium, typically a culture medium containing higher concentrations of components (such as nutrients and amino acids) consumed during cell culture production, can be used to supplement and maintain active cultures, particularly cultures in batch feed, semi-perfusion or perfusion modes. This concentrated feed medium can contain most of the cell culture medium components, for example, about 5×, 6×, 7×, 8×, 9×, 10×, 12×, 14×, 16×, 20×, 30×, 50×, 100×, 200×, 400×, 600×, 800× or even about 1000× of their normal amounts.
[0132] The vegetative phase can be carried out at a higher temperature than the production phase. For example, the vegetative phase can be carried out at a first temperature of about 35°C to about 38°C, and the production phase can be carried out at a second temperature of about 29°C to about 37°C, optionally about 30°C to about 36°C or about 30°C to about 34°C. Chemical inducers of protein production, such as caffeine, butyrate, and hexamethylenebisacetamide (HMBA), can be added before and / or after the temperature change, or in place of the temperature change. If the inducer is added after the temperature change, the inducer can be added 1 hour to 5 days after the temperature change, optionally 1 to 2 days after the temperature change.
[0133] Host cells can be cultured in suspension or adherent form, attached to a solid matrix. Cell cultures can be established in fluidized bed bioreactors, hollow fiber bioreactors, roller bottles, shake flasks, or stirred tank bioreactors with or without microcarriers.
[0134] Cell culture can be performed in batch, fed-batch, continuous, semi-continuous, or perfusion modes. Mammalian cells (such as CHO cells) can be cultured in bioreactors at small scales of less than 100 ml to less than 1000 ml, at medium scales with capacities of 2,000 liters or more, and at larger scales with capacities exceeding 20,000 liters. Medium and large-scale cell cultures, such as those used for clinical and / or commercial-scale biomanufacturing of protein therapeutics, can be maintained for weeks or even months, during which time the cells produce the desired protein or proteins.
[0135] The expressed recombinant protein produced can then be harvested from the cell culture medium. Methods for harvesting proteins from suspended cells are known in the art and include, but are not limited to, acid precipitation, accelerated sedimentation (such as flocculation), separation using gravity, centrifugation, sonication, filtration (including membrane filtration using ultrafilters, microfilters, tangential flow filters, alternative tangential flow filters, depth filters, and alluvial filters). Recombinant proteins expressed by prokaryotes are recovered from inclusion bodies in the cytoplasm by methods involving redox folding processes known in the art.
[0136] One or more unit operations can then be used to purify or partially purify the harvested protein from any impurities, such as remaining cell culture medium, cell extracts, unwanted components, host cell proteins, incorrectly expressed proteins, etc. The term "unit operation" refers to a functional step performed as a part of a process for purifying a recombinant protein of interest. For example, a unit operation can include, but is not limited to, steps for capturing, purifying, refining, inactivating viruses, filtering viruses, concentrating, and / or preparing a recombinant protein of interest. Unit operations can be designed to achieve a single goal or multiple goals, such as capturing and inactivating viruses steps. Unit operations can also include holding or storage steps between processing steps.
[0137] The capture unit operation may include capture chromatography using resins and / or membranes containing reagents that bind to the recombinant protein of interest, such as affinity chromatography, size exclusion chromatography, ion exchange chromatography, hydrophobic interaction chromatography (HIC), immobilized metal affinity chromatography (IMAC), and the like. Such materials are known in the art and are commercially available. Affinity chromatography, for example, can utilize a capture mechanism that binds to an antibody or antibody fragment, such as protein A, protein G, protein A / G, or protein L. The recombinant protein of interest can be labeled with a polyhistidine tag and subsequently purified by IMAC using imidazole, or using an epitope such as ) tag and then purified using a specific antibody against this epitope.
[0138] Unit operations that include inactivating, reducing and / or eliminating viral contaminants can include processes that manipulate the environment and / or filtration. One way to achieve viral inactivation is to incubate at low pH (e.g., pH <4) or other solution conditions (such as temperature or chemical composition) to achieve viral inactivation. After low pH viral inactivation, a neutralization unit operation can be performed that readjusts the virally inactivated solution to a pH value that is more consistent with the requirements of subsequent unit operations. Filtration, such as depth filtration, can also be performed subsequently to remove any resulting turbidity or precipitation. Virus filtration can be performed using a microfilter or nanofilter, such as those available from Asahi Kasei Corporation. and EDM Millipore Those obtained.
[0139] The polishing unit operation can utilize various chromatographic methods to purify the target protein and remove contaminants and impurities, such as DNA, host cell proteins; remove product-specific impurities, variant products and aggregates, viral adsorption, etc. The resins and / or membranes used in the polishing chromatography unit operation contain reagents that can be used in a "flow-through mode" (where the target protein is contained in the eluent and the contaminants and impurities are bound to the chromatography medium) or a "bind and elute mode" where the target protein is bound to the chromatography medium and eluted after the contaminants and impurities flow through the chromatography medium or are washed off the chromatography medium. Examples of such chromatographic methods include ion exchange chromatography (IEX), such as anion exchange chromatography (AEX) and cation exchange chromatography (CEX); hydrophobic interaction chromatography (HIC); mixed-mode or multimodal chromatography (MM), hydroxyapatite chromatography (HA); reversed-phase chromatography and gel filtration, to name a few.
[0140] Product concentration and buffer exchange of the target protein into the desired formulation buffer for bulk storage of the drug substance can be achieved by ultrafiltration and diafiltration.
[0141] Can measure key attribute and performance parameter, to better guide the decision-making of each step performance in relevant manufacturing process.These key attributes and parameter can real-time monitoring, near real-time monitoring and / or afterwards monitoring.Can measure main key parameter, such as the level of the culture medium components (such as glucose) of consumption, the metabolic byproducts (such as lactic acid and ammonia) of accumulation and the parameter relevant with cell maintenance and survival, such as dissolved oxygen content.Key attribute, such as specific productivity, viable cell density, pH, molar osmotic pressure concentration, outward appearance, color, aggregation, yield percentage and titer, can be monitored in process and after process.Can use known technology and commercially available equipment to monitor and measure.
[0142] Titer can be measured using methods known in the art. For example, titer can be measured by reversed-phase HPLC analysis using affinity chromatography, in which protein A is immobilized on a column support. At neutral pH, the antibody molecule binds to protein A via the Fc region, while host cell proteins, conditioned medium components, and buffer are eluted from the chromatographic column during circulation. The captured antibody is eluted at acidic pH and detected by UV absorption at 280 nm. A calibration curve can be obtained from universal antibody standards and corresponding peak areas using linear regression analysis. The concentration of the antibody in the test sample is then calculated based on the calibration curve and the ratio of the extinction coefficients of the universal antibody standards and the tested antibody.
[0143] Other methods include, but are not limited to, ELISA; HTRF (homogeneous time-lapse fluorescence) (CisbioUS, Bedford, MA); and Berkley Lights Beacon platform (Emeryville, CA).
[0144] Also provided is a pharmaceutical composition comprising a recombinant protein of interest expressed by a cell host, the host cell being transfected with a vector comprising an engineered nucleic acid molecule encoding piggyBac transposase. Such pharmaceutical compositions include cells expressing a protein of interest or a protein of interest, such as immune cells expressing CAR and TCR, and one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Such compositions may include a buffer, such as a neutral buffered saline solution, a phosphate buffered saline solution, etc.; carbohydrates, such as glucose, mannose, sucrose or dextran, mannitol; protein; polypeptide or amino acid, such as glycine; antioxidant; chelating agent, such as EDTA or glutathione; adjuvant (e.g., aluminum hydroxide); and a preservative.
[0145] These pharmaceutical compositions (solutions, suspensions, etc.) may contain one or more of the following: a sterile diluent, such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, a fixed oil, such as synthetic monoglycerides or diglycerides, polyethylene glycol, glycerol, propylene glycol, or other solvents that can be used as a solvent or suspending medium; an antibacterial agent, such as benzyl alcohol or methyl paraben; an antioxidant, such as ascorbic acid or sodium bisulfite; a chelating agent, such as ethylenediaminetetraacetic acid; a buffer, such as acetate, citrate or phosphate; and an agent for adjusting tonicity, such as sodium chloride or glucose. Parenteral preparations can be packaged in ampoules, disposable syringes, or multiple-dose vials made of glass or plastic.
[0146] In one embodiment, the present invention provides a method for improving the titer of a recombinant protein of interest expressed by a host cell, the method comprising engineering a nucleic acid molecule encoding a piggyBac transposase to increase stability in the host cell, co-transfecting the host cell with the engineered nucleic acid molecule encoding the piggyBac transposase and a vector comprising a nucleic acid sequence encoding a protein of interest flanked by at least 5' and 3' inverted repeat elements of the piggyBac transposon, and culturing the cells to express the recombinant protein of interest, wherein the titer of the recombinant protein of interest expressed by the host cell transfected with the engineered piggyBac transposase is improved compared to the titer of the recombinant protein of interest expressed by the host cell transfected with the engineered piggyBac transposase or not transfected with the piggyBac transposase. In a related embodiment, the host cell is transfected with a first vector comprising the engineered nucleic acid molecule encoding the piggyBac transposase and a second vector comprising a nucleic acid sequence encoding the protein of interest flanked by at least 5' and 3' inverted repeat elements of the piggyBac transposon. In a related embodiment, the host cell is transfected with a single vector comprising an engineered nucleic acid molecule encoding a piggyBac transposase and a nucleic acid sequence encoding a protein of interest flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon. In one embodiment, an engineered nucleic acid molecule encoding a piggyBac transposase as described herein is provided. In one embodiment, a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, or SEQ ID NO:18 is provided. In another aspect, the invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7. In another aspect, the invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 9 or SEQ ID NO: 11. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 17 or SEQ ID NO: 18. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 3.In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:5. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:7. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:9. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:11. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:13. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:15. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:17. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:18.
[0147] In one embodiment, a piggyBac transposase is provided, comprising an amino acid substitution at one or more of positions 147, 176, 221, 247, 429, 533, and 573 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of threonine for serine at one or more of positions 429, 533, and 573 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO: 2, and / or an amino acid substitution of threonine for serine at one or more of positions 429, 533, and 573 of SEQ ID NO: 2. In related embodiments, the piggyBac transposase comprises at least one of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO: 2. In related embodiments, the piggyBac transposase comprises at least two of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO: 2. In another related embodiment, the piggyBac transposase comprises a substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, a substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and a substitution of threonine for serine at position 533 of SEQ ID NO: 2. In one embodiment, a piggyBac transposase is provided, the piggyBac transposase having the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. In another aspect, the present invention provides a piggyBac transposase having the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, or SEQ ID NO: 8.In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 12. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 4. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 6. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 8. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 10. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 12. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 14. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 16.
[0148] In one embodiment, the present invention provides a method for increasing the production of a recombinant protein in a mammalian cell culture expressing a recombinant protein, the method comprising establishing a cell culture in a bioreactor using host cells that have been co-transfected with a nucleic acid molecule engineered to increase stability in the host cells and a vector comprising a nucleic acid molecule encoding a protein of interest flanked by at least inverted repeat elements of a piggyBac transposon; and expressing the recombinant protein of interest; wherein the titer of the recombinant protein of interest expressed by the host cells transfected with the engineered piggyBac transposase is improved compared to the titer of the recombinant protein of interest expressed by host cells transfected with wild-type piggyBac transposase or not transfected with piggyBac transposase. In a related embodiment, the host cells are transfected with a first vector comprising an engineered nucleic acid molecule encoding the piggyBac transposase and a second vector comprising a nucleic acid sequence encoding the protein of interest flanked by at least 5' and 3' inverted repeat elements of the piggyBac transposon. In a related embodiment, the host cell is transfected with a single vector comprising an engineered nucleic acid molecule encoding a piggyBac transposase and a nucleic acid sequence encoding a protein of interest flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon. In one embodiment, an engineered nucleic acid molecule encoding a piggyBac transposase as described herein is provided. In one embodiment, a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, or SEQ ID NO:18 is provided. In another aspect, the invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7. In another aspect, the invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 9 or SEQ ID NO: 11. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 17 or SEQ ID NO: 18. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 3. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 5.In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:7. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:9. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:11. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:13. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:15. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:17. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:18.
[0149] In one embodiment, a piggyBac transposase is provided, comprising an amino acid substitution at one or more of positions 147, 176, 221, 247, 429, 533, and 573 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of threonine for serine at one or more of positions 429, 533, and 573 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO: 2, and / or an amino acid substitution of threonine for serine at one or more of positions 429, 533, and 573 of SEQ ID NO: 2. In related embodiments, the piggyBac transposase comprises at least one of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO: 2. In related embodiments, the piggyBac transposase comprises at least two of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO: 2. In another related embodiment, the piggyBac transposase comprises a substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, a substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and a substitution of threonine for serine at position 533 of SEQ ID NO: 2. In one embodiment, a piggyBac transposase is provided, the piggyBac transposase having the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. In another aspect, the present invention provides a piggyBac transposase having the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, or SEQ ID NO: 8.In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 12. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 4. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 6. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 8. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 10. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 12. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 14. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 16.
[0150] In one embodiment, the present invention provides a method for producing an isolated and purified recombinant protein of interest, the method comprising establishing a cell culture in a bioreactor with host cells expressing the recombinant protein of interest, wherein the cell line has been co-transfected with a nucleic acid sequence encoding a piggyBac transposase and a vector comprising a nucleic acid sequence encoding a protein of interest, the nucleic acid sequence encoding the piggyBac transposase being engineered for increased stability in the host cell, the protein of interest being flanked by at least 5' and 3' inverted repeat elements of the piggyBac transposon; culturing the cells to express the recombinant protein of interest; harvesting the recombinant protein of interest, processing the recombinant protein of interest through one or more unit operations, and obtaining an isolated and purified recombinant protein of interest. In a related embodiment, the host cells are transfected with a first vector comprising an engineered nucleic acid molecule encoding the piggyBac transposase and a second vector comprising a nucleic acid sequence encoding the protein of interest, the protein of interest being flanked by at least 5' and 3' inverted repeat elements of the piggyBac transposon. In a related embodiment, the host cell is transfected with a single vector comprising an engineered nucleic acid molecule encoding a piggyBac transposase and a nucleic acid sequence encoding a protein of interest flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon. In a related embodiment, at least one unit operation is a capture chromatography step selected from affinity chromatography, ion exchange chromatography, anion exchange chromatography, cation exchange chromatography, multimodal chromatography, hydrophobic interaction chromatography, and hydroxyapatite chromatography. In another embodiment, at least one unit operation is a polishing chromatography step selected from ion exchange chromatography, anion exchange chromatography, cation exchange chromatography, multimodal chromatography, hydrophobic interaction chromatography, and hydroxyapatite chromatography. In another embodiment, at least one unit operation is selected from viral inactivation, viral filtration, depth filtration, and UF / DF. In a related embodiment, the titer of the recombinant protein of interest expressed by host cells transfected with the engineered piggyBac transposase is improved compared to the titer of the recombinant protein of interest expressed by host cells transfected with wild-type piggyBac transposase or not transfected with piggyBac transposase. In another embodiment, an isolated and purified recombinant protein of interest produced by the method is provided. In another embodiment, a pharmaceutical composition comprising the isolated protein of interest is provided. In one embodiment, an engineered nucleic acid molecule encoding a piggyBac transposase as described herein is provided. In one embodiment, a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, or SEQ ID NO:18 is provided.In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:9 or SEQ ID NO:11. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:17 or SEQ ID NO:18. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:5. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:7. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:9. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 11. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 13. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 15. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 17. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 18.
[0151] In one embodiment, a piggyBac transposase is provided, comprising an amino acid substitution at one or more of positions 147, 176, 221, 247, 429, 533, and 573 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of threonine for serine at one or more of positions 429, 533, and 573 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO: 2, and / or an amino acid substitution of threonine for serine at one or more of positions 429, 533, and 573 of SEQ ID NO: 2. In related embodiments, the piggyBac transposase comprises at least one of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO: 2. In related embodiments, the piggyBac transposase comprises at least two of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO: 2. In another related embodiment, the piggyBac transposase comprises a substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, a substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and a substitution of threonine for serine at position 533 of SEQ ID NO: 2. In one embodiment, a piggyBac transposase is provided, the piggyBac transposase having the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. In another aspect, the present invention provides a piggyBac transposase having the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, or SEQ ID NO: 8.In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 12. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 4. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 6. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 8. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 10. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 12. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 14. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 16.
[0152] In one embodiment, the present invention provides a kit for transfecting cells, the kit comprising a vector containing a nucleic acid sequence encoding a piggyBac transposase, the nucleic acid sequence encoding the piggyBac transposase being engineered to increase stability in the host cell; and a vector comprising at least the minimal inverted repeat element of the piggyBac transposon, into which a nucleic acid sequence encoding a protein of interest is inserted. In one embodiment, an engineered nucleic acid molecule encoding a piggyBac transposase as described herein is provided. In one embodiment, a piggyBac transposase encoded by a nucleic acid sequence of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, or SEQ ID NO:18 is provided. In another aspect, the present invention provides a piggyBac transposase encoded by a nucleic acid sequence of SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 11, SEQ ID NO: 13 or SEQ ID NO: 15. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 9 or SEQ ID NO: 11. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 17 or SEQ ID NO: 18. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 3. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 5. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 7. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 9. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 11. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 13. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 15. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 17. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 18.
[0153] In one embodiment, a piggyBac transposase is provided, comprising an amino acid substitution at one or more of positions 147, 176, 221, 247, 429, 533, and 573 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of threonine for serine at one or more of positions 429, 533, and 573 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO: 2, and / or an amino acid substitution of threonine for serine at one or more of positions 429, 533, and 573 of SEQ ID NO: 2. In related embodiments, the piggyBac transposase comprises at least one of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO: 2. In related embodiments, the piggyBac transposase comprises at least two of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO: 2. In another related embodiment, the piggyBac transposase comprises a substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, a substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and a substitution of threonine for serine at position 533 of SEQ ID NO: 2. In one embodiment, a piggyBac transposase is provided, the piggyBac transposase having the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. In another aspect, the present invention provides a piggyBac transposase having the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, or SEQ ID NO: 8.In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 12. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 4. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 6. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 8. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 10. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 12. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 14. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 16.
[0154] The piggyBac transposase described herein can be used as part of the piggyBac transposon system for gene transfer; production of cell lines; applications related to genetic engineering, such as genetically modifying cells, generating genome modifications; for germline or somatic mutagenesis; for mediating gene transfer; characterizing genes; determining gene function; oncogene screening; gene therapy; generation of pluripotent stem cells; and non-human transgenic animals (see, e.g., US 2013 / 0209426; US 2010 / 0311116; Vanden Driessche et al., Blood 114(8):1461-1468, 2009; Yusa K, et al., Nat. Methods. 6(5):363-369, 2009; Wilson et al., Mol. Ther. 15(1):139-145, 2007; Landrette et al., PLoS ONE [Public Library of Science One] 6(10):1-12, 2011; Nakanishi et al., Molecular Therapy [Molecular Therapy] 18(4):707-714, 2010); Zhao et al., Transl Lung Cancer Res. [Lung Cancer Translational Research], 5(1):120-125, 2016; Wilson et al., Molecular Therapy [Molecular Therapy] 15(1):139-145, 2007).
[0155] The piggyBac transposase described herein can be used for genome editing. The piggyBac transposase described herein can be used as a part of the piggyBac transposon / transposase system, and its benefit is that it provides effective non-viral delivery to be integrated into primary cell types or stem cells. The piggyBac transposase described herein can be used for non-viral delivery of genes encoding chimeric antigen receptors (CAR), T cell receptors (TCR) α and β chains, and other genes encoding proteins (such as cytokines, checkpoint inhibitors and other proteins) to engineered cells. Multiple genes can be delivered in a single gene construct. The advantage compared to viral transduction is that a larger gene carrying capacity can be accommodated, and the transposase can improve the efficiency of integration in non-viral transfection. This system can also be used in combination with other non-viral genome editing technologies, such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), clustered regularly interspaced short palindromic repeats-(CRISPR-) associated protein 9 (Cas9), integrases (such as PhiC3 integrase), transcription activator-like effectors (TALES), sequence-specific recombinases and other transposon / transposase systems (such as Sleeping Beauty) to achieve transduction in a variety of cells (US2015 / 0031132; WO 2018 / 098671; Ivics et al., Cell 91(4):501-510, 1997; Boch et al., Science 326(5959):1509-1512, 2009; Christian et al., Genetics 186(2):757-761, 2010; Wilber et al., Stem Cells Int [International Stem Cell Research]; Volume: 2011: Article No. 717069, 2011; Yusa et al., Nature [Nature] 478, October 20, 391-396, 2011; Silva et al., Curr Gene Ther [Current Gene Ther] 11(1): 11-27, 2011; Cong et al., Science [Science] 339(6121): 819-823, 2013; Mali et al., Science [Science] 339(6121): 823-826, 2013. Li et al., Molecular Therapy: Nucleic Acids [Molecular Therapy: Nucleic Acids] Volume 8 September, 64-76, 2017; and Ishida et al., www.nature / Scientific Reports 8, Article No. 310, 2018).
[0156] The piggyBac transposase described herein can be used as part of the piggyBac transposon system to stably transfect cells with gene constructs encoding CAR, TCR and / or other proteins in a non-viral manner. Natural T cells can be (i) removed from the patient (subject) or donor, (ii) genetically engineered using the piggyBac transposon / transposase system comprising the piggyBac transposase described herein to express one or more chimeric antigen receptors, T cell receptors and / or other proteins bound to at least one antigen of interest, (iii) expanded into more engineered T cell populations by cell culture, and (iv) reintroduced into the patient. After the engineered T cells are reintroduced into the patient, they mediate an immune response against cells expressing the antigen. See, e.g., U.S. Patent Nos. 7,741,465 and 6,319,494; U.S. Patent Publication No. 2017 / 0355957; Nakazawa et al., J. Immunotherapy 32(8):826-836; 2009; Nakazawa et al., Molecular Therapy 19(12):2133-2143, 2011; Eshhar et al., Cancer Immunol Immunotherapy (1997) 45:131-136; Finney et al., Journal of of Immunology, 161:2791-2797, 1998; Krause et al., J. Exp. Med., 188(4):619-626, 1998; This immune response includes the secretion of IL-2 and other cytokines by T cells, the clonal expansion of T cells that recognize the antigen, and the specific killing of positive target cells by T cells. See Hombach et al., Journal of Immunology, 167:6123-6131 (2001).
[0157] Immune cells can be obtained from a subject. In some embodiments, immune cells comprise T cells. T cells can be obtained from many sources, including peripheral blood mononuclear cells (PBMC), bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue from an infection site, ascites, pleural effusion, spleen tissue, and tumors. In certain embodiments, T cells can be isolated using any number of techniques known to those skilled in the art (such as FICOLL TMThe cells are preferably obtained from a unit of blood collected from a subject by apheresis. The apheresis product typically contains lymphocytes (including T cells), monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets. In certain embodiments, the cells collected by apheresis can be washed to remove the plasma fraction and placed in a suitable buffer or culture medium for subsequent processing. The cells can be washed with PBS. It should be appreciated that a washing step can be used, such as by using a semi-automatic flow-through centrifuge - e.g., a Cobe TM 2991 Cell Processor, Baxter CytoMate TM After washing, the cells can be resuspended in a variety of biocompatible buffers or other saline solutions with or without buffers. In certain embodiments, undesirable components of the aliquoted sample can be removed.
[0158] In certain embodiments, T cells are isolated from PBMCs by lysing red blood cells and depleting monocytes, e.g., using a PERCOLL TM Gradient centrifugation. Specific subsets of T cells, such as CD28, can be further isolated by positive or negative selection techniques known in the art. + 、CD4 + 、CD8 + 、CD45RA + and CD45RO + T cells. For example, enrichment of T cell populations by negative selection can be achieved using a combination of antibodies against surface markers specific to the negatively selected cells. One method used herein is cell sorting and / or selection via negative magnetic immunoadhesion or flow cytometry, which uses a mixture of monoclonal antibodies against cell surface markers present on the negatively selected cells. For example, to enrich CD4 + Cells, monoclonal antibody cocktails typically include antibodies against CD14, CD20, CD11b, CD16, HLA-DR and CD8. Flow cytometry and cell sorting can also be used to isolate cell populations of interest for use in the present invention.
[0159] PBMC can be directly used for using method as described herein to adopt gene construct (such as CAR or TCR) to carry out genetic modification.In certain embodiments, after separation of PBMC, T lymphocyte can be further separated, and cytotoxicity and helper T lymphocyte can be sorted as initial, memory and effector T cell subsets before or after genetic modification and / or amplification.
[0160] In some embodiments, by identifying CD8 + Each relevant cell surface antigen on the cell, CD8 +The cells are further sorted into naive, central memory, and effector cells. In some embodiments, the central memory T cells express phenotypic markers including CD45RO, CD62L, CCR7, CD28, CD3, and CD127, and are negative for granzyme B. In some embodiments, the central memory T cells are CD45RO + 、CD62L + 、CD8 + T cells. In some embodiments, the effector T cells are negative for CD62L, CCR7, CD28, and CD127, and positive for granzyme B and perforin. In certain embodiments, CD4 + T cells can be further sorted into subsets. For example, CD4 + T helper cells are sorted into naive, central memory, and effector cells.
[0161] These immune cells, such as T cells, can be genetically modified using one or more vectors after separation, and the one or more vectors include one or more nucleotide sequences encoding one or more CARs and piggyBac transposases as described herein, as part of the piggyBac transposon / transposase system.Non-viral gene modified immune cells can be obtained by transfecting cells with at least one nucleic acid sequence comprising a vector encoding piggyBac transposase as described herein and encoding at least one CAR, TCR and / or other proteins of interest (its flanks are at least 5' and 3' inverted repeat elements of piggyBac transposons).Genetically modified immune cells can also be obtained by co-transfecting immune cells with a first vector comprising an engineered nucleic acid molecule encoding piggyBac transposase as described herein and a second vector comprising at least one nucleic acid sequence encoding at least one CAR, TCR and / or other proteins of interest (its flanks are at least 5' and 3' inverted repeat elements of piggyBac transposons).These vectors can be introduced into host cells using any suitable method known in the art, such as by electroporation or nuclear transfection. In another embodiment, a mixture of different expression vectors can be used to genetically modify a donor immune effector cell population, wherein each vector encodes a different CAR, TCR, or other target protein. The resulting transformed immune effector cells form a mixed engineered cell population, wherein a portion of the engineered cells express more than one different CAR, TCR, and / or other target protein.
[0162] Also included is an enzyme that allows selective elimination of modified cell suicide genes after prodrug administration by encoding an enzyme that causes a functionally active toxic product, which is conducive to the activation of apoptosis or inhibits cell proliferation, thereby minimizing adverse events. Inducible "on" or "accelerator" switches may also be included. Suitable techniques include using inducible caspase-9 (U.S. published application 2011 / 0286980) or thymidine kinase before, after, or simultaneously with transfection of cells with CAR or TCR constructs. Additional methods for introducing suicide genes and / or "on" switches include TALENS, zinc fingers, RNAi, siRNA, shRNA, antisense technology, and other technologies known in the art.
[0163] Prior to genetic modification, immune cells can be activated and expanded in vitro (or differentiated if progenitor cells). Methods for activating and expanding T cells are known in the art and are described in, for example, U.S. Patent No. 6,905,874; U.S. Patent No. 6,867,041; U.S. Patent No. 6,797,514; and PCT WO 2012 / 079000. Typically, such methods involve contacting PBMCs or isolated T cells with stimulatory and costimulatory agents, such as anti-CD3 and anti-CD28 antibodies, typically attached to beads or other surfaces, in a culture medium with appropriate cytokines such as IL-2. The anti-CD3 and anti-CD28 antibodies attached to the same beads act as "surrogate" antigen presenting cells (APCs). An example is System, a CD3 / CD28 activator / stimulatory system for physiological activation of human T cells.
[0164] In other embodiments, T cell proliferation can be activated and stimulated with feeder cells and appropriate antibodies and cytokines using methods such as those described in: US Patent No. 6,040,177; US Patent No. 5,827,642; and WO2012129514, the contents of which are herein incorporated by reference in their entireties.
[0165] PBMCs may further include other cytotoxic lymphocytes, such as NK cells, NKT cells or hematopoietic stem cells.An expression vector carrying the coding sequence of a chimeric receptor as disclosed herein can be introduced into a population of human donor T cells, NK cells, NKT cells, monocytes or hematopoietic stem cells.
[0166] Standard procedures are used to store cells expressing CAR or TCT in cold storage for storage and / or preparation for use in human subjects. This involves cold storage of immune cells so that the cells remain viable after thawing. A portion of the immune cells expressing CAR can be stored in cold storage by methods known in the art to provide a permanent source of such cells for future treatment of patients with malignant tumors. When needed, the frozen transformed immune cells can be thawed, grown, and expanded to obtain more such cells.
[0167] As used herein, "cold storage" refers to preserving cells by cooling to subzero temperatures, such as (typically) 77 Kelvin or -196°C. Cryoprotectants are typically used at subzero temperatures to protect cells from damage caused by freezing or warming to room temperature. Cryopreservatives and optimal cooling rates can prevent cell damage and are known in the art. Cryoprotectants include, but are not limited to, dimethyl sulfoxide (DMSO) (Lovelock & Bishop, Nature (1959); 183: 1394-1395; Ashwood-Smith, Nature (1961); 190: 1204-1205), glycerol, povidone (Rinfret, Ann. NY Acad. Sci. [Annals of the New York Academy of Sciences] (1960); 85: 576) and polyethylene glycol (Sloviter & Ravdin, Nature (1962); 196: 48).
[0168] The cells are then formulated for reintroduction into the subject. The cells are formulated in a therapeutically effective amount by first harvesting the cells from the cell culture medium, then washing and concentrating the cells in a medium and container system suitable for administration (a "pharmaceutically acceptable" carrier). Suitable infusion media can be any isotonic medium formulation, typically normal saline, Normosol, or a combination thereof. TM R (Abbott) or Plasma-Lyte TM A (Baxter), but 5% dextrose in water or Ringer's lactate may also be used. The infusion medium may be supplemented with human serum albumin.
[0169] The desired therapeutic amount of cells in the composition is generally at least 2 cells (e.g., at least 1 CD8 + Central memory T cells and at least 1 CD4 + helper T cell subsets) or more typically greater than 10 2 cells, and up to 10 6 up to and including 10 8 or 10 9 cells, and can exceed 10 10The number of cells depends on the intended use of the composition and the type of cells contained therein. The cells can be autologous, allogeneic, or xenogeneic to the patient being treated.
[0170] Cell populations expressing CARs, TCRs, and / or other proteins of interest can be administered alone or as pharmaceutical compositions in combination with a diluent and / or with other components such as IL-2 or other cytokines or cell populations.
[0171] Provided are methods for treating conditions, diseases or disorders using these engineered cells.Such conditions, diseases or disorders include cancer, tumors, solid tumors, blood disorders, leukemias, lymphomas, viral infections, inflammatory diseases or disorders and / or autoimmune diseases or disorders. In certain embodiments, the present invention relates to producing a T cell-mediated immune response in a subject, including administering an effective amount of the engineered immune cells of the present application to the subject. In certain embodiments, the T cell-mediated immune response is directed to a target cell or cell. In certain embodiments, the engineered immune cell comprises a gene construct expressing one or more chimeric antigen receptors (CARs), T cell receptors (TCRs) and / or other proteins of interest. In certain embodiments, the target cell is a tumor cell. In some aspects, the present invention includes methods for treating or preventing malignant tumors, comprising administering an effective amount of at least one separated antigen binding molecules as described herein to a subject in need. In certain embodiments, the present invention includes methods for treating or preventing malignant tumors, comprising administering an effective amount of at least one immune cell to a subject in need, wherein the immune cell comprises a gene construct encoding at least one chimeric antigen receptor as described herein, T cell receptor and / or separated antigen binding molecules. In some aspects, the present invention includes methods for treating or preventing inflammatory and / or autoimmune diseases. The present invention also provides methods for using to support transplantation procedures, such as cell therapy for mismatched HLA molecules on transplanted tissues / organs. In some embodiments, the target cells are pancreatic islets.
[0172] In one embodiment, the present invention provides a method for producing non-viral genetically modified cells, the method comprising: (a) creating a vector comprising at least one nucleic acid sequence encoding at least one protein of interest, the protein of interest being flanked by at least the 5' and 3' inverted repeat elements of a piggyBac transposon; (b) isolating natural immune cells from a donor or subject; (b) co-transfecting these host cells with an engineered nucleic acid molecule encoding a piggyBac transposase and a vector comprising at least one nucleic acid sequence encoding at least one protein of interest, the protein of interest being flanked by at least the 5' and 3' inverted repeat elements of a piggyBac transposon; and (c) expanding these cells into a larger population of non-viral genetically modified cells by cell culture. In one embodiment, the cells are transfected with a vector comprising at least one nucleic acid sequence encoding at least one protein of interest and a vector comprising a nucleic acid sequence encoding a piggyBac transposase, the nucleic acid sequence encoding the piggyBac transposase being engineered for increased stability in the cell. In one embodiment, an engineered nucleic acid molecule encoding a piggyBac transposase as described herein is provided. In one embodiment, cells are transfected with a vector comprising at least one nucleic acid sequence encoding at least one protein of interest flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon and a nucleic acid sequence encoding the piggyBac transposase, the nucleic acid sequence encoding the piggyBac transposase being engineered to increase stability in the cell. In one embodiment, an engineered nucleic acid molecule encoding a piggyBac transposase as described herein is provided. In one embodiment, a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, or SEQ ID NO:18 is provided. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 11, SEQ ID NO: 13, or SEQ ID NO: 15. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 9 or SEQ ID NO: 11. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 17 or SEQ ID NO: 18.In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:5. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:7. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:9. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:11. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:13. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:15. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:17. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:18.
[0173] In one embodiment, a piggyBac transposase is provided, comprising an amino acid substitution at one or more of positions 147, 176, 221, 247, 429, 533, and 573 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of threonine for serine at one or more of positions 429, 533, and 573 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO: 2, and / or an amino acid substitution of threonine for serine at one or more of positions 429, 533, and 573 of SEQ ID NO: 2. In related embodiments, the piggyBac transposase comprises at least one of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO: 2. In related embodiments, the piggyBac transposase comprises at least two of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO: 2. In another related embodiment, the piggyBac transposase comprises a substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, a substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and a substitution of threonine for serine at position 533 of SEQ ID NO: 2. In one embodiment, a piggyBac transposase is provided, the piggyBac transposase having the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. In another aspect, the present invention provides a piggyBac transposase having the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, or SEQ ID NO: 8.In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 12. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 4. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 6. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 8. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 10. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 12. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 14. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 16.
[0174] In one embodiment, the present invention provides a method for treating a subject with non-viral genetically modified cells, the method comprising: (a) engineering a nucleic acid molecule encoding a piggyBac transposase to increase its stability in cells and inserting it into a vector; (b) isolating natural immune cells from a subject or donor; (c) co-transfecting these host cells with the engineered nucleic acid molecule encoding the piggyBac transposase and a vector comprising at least one nucleic acid sequence encoding at least one protein of interest, the protein of interest being flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon; (d) expanding the cells into a larger population of genetically modified cells by cell culture; (e) isolating the transformed cells from the cell culture to obtain a population of cells comprising genetically modified cells; and (f) reintroducing the non-viral genetically modified cells into the subject. In one embodiment, a piggyBac transposase encoded by a nucleic acid sequence of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 18 is provided. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:9 or SEQ ID NO:11. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:17 or SEQ ID NO:18. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:5. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:7. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:9. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 11. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 13. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 15.In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 17. In another aspect, the present invention provides a piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO: 18.
[0175] In one embodiment, a piggyBac transposase is provided, comprising an amino acid substitution at one or more of positions 147, 176, 221, 247, 429, 533, and 573 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of threonine for serine at one or more of positions 429, 533, and 573 of SEQ ID NO: 2. In a related embodiment, the piggyBac transposase comprises an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221, and 247 of SEQ ID NO: 2, and / or an amino acid substitution of threonine for serine at one or more of positions 429, 533, and 573 of SEQ ID NO: 2. In related embodiments, the piggyBac transposase comprises at least one of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO: 2. In related embodiments, the piggyBac transposase comprises at least two of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO: 2. In another related embodiment, the piggyBac transposase comprises a substitution of leucine for isoleucine at position 147 of SEQ ID NO: 2, a substitution of leucine for isoleucine at position 247 of SEQ ID NO: 2, and a substitution of threonine for serine at position 533 of SEQ ID NO: 2. In one embodiment, a piggyBac transposase is provided, the piggyBac transposase having the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. In another aspect, the present invention provides a piggyBac transposase having the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, or SEQ ID NO: 8.In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 12. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 4. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 6. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 8. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 10. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 12. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 14. In another aspect, the present invention provides a piggyBac transposase having an amino acid sequence of SEQ ID NO: 16.
[0176] In a related embodiment, the innate immune cell is a monocyte. In a related embodiment, the innate immune cell is a T cell. In another embodiment, the protein of interest is an antigen receptor, a T cell receptor, or a chimeric antigen receptor. In another embodiment, the cell is further transfected with a nucleic acid molecule encoding a suicide gene, i.e., an inducible on or accelerator switch, or both. In one embodiment, an engineered nucleic acid molecule encoding a piggyBac transposase as described herein is provided.
[0177] In one embodiment, the innate immune cells are transfected with a vector comprising an engineered nucleic acid molecule encoding a piggyBac transposase and a vector comprising at least one nucleic acid sequence encoding at least one protein of interest flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon.
[0178] In one embodiment, the innate immune cells are transfected with a single vector comprising an engineered nucleic acid molecule encoding a piggyBac transposase and at least one nucleic acid sequence encoding at least one protein of interest flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon.
[0179] In one embodiment, the vector comprises bicistronic or polycistronic constructs encoding multiple proteins of interest.
[0180] The present invention also provides non-viral genetically modified cells, cell populations or cell cultures prepared according to the methods described herein. Also provided are preparations comprising genetically modified cells or cell populations prepared by the methods described herein.
[0181] Also provided are methods for treating or preventing a disease or disorder in a donor or subject in need thereof, the methods comprising administering to the donor or subject an effective amount of a genetically modified cell or cell population prepared by the methods described herein. In another embodiment, a pharmaceutical composition is provided, comprising an isolated, purified protein of interest prepared according to the methods described herein.
[0182] Although the terms used in this application are standard terms in the art, the definition of certain terms is provided herein to ensure the clarity and certainty of the meaning of the claims. Units, prefixes and symbols may be expressed in their SI (International System of Units) acceptance form. The numerical ranges listed herein include the numerals defining the ranges, and include and support each integer within the defined range. Unless otherwise indicated, the methods and techniques described herein can be carried out according to conventional methods well known in the art and as described throughout the various general and more specific references cited and discussed in this specification. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual [Molecular Cloning: Laboratory Manual], 3rd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (2001) and Ausubel et al., Current Protocols in Molecular Biology [Molecular Biology Experiment Guide], Green Publishing Company (1992), and Harlow and Lane Antibodies: A Laboratory Manual [Antibodies: Laboratory Manual] Cold Spring Harbor Laboratory Press [Cold Spring Harbor Laboratory Press], Cold Spring Harbor, New York (1990). All documents or parts of documents cited in this application, including but not limited to patents, patent applications, papers, books, and monographs, are expressly incorporated herein by reference. Contents described in one aspect or embodiment of the present invention may be combined with other aspects and / or embodiments of the present invention.
[0183] The present invention is not limited in scope by the specific embodiments described herein, which are intended as single illustrations of various aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to be encompassed within the scope of the appended claims.
[0184] Examples
[0185] Example 1 Identification and testing of mutations
[0186] The structure of piggyBac transposase and other related transposases is still unclear. We used a computer method called DSC (King, RD et al., Protein Sci. [Protein Science] 5(11): 2298-2310, 1996) to predict the secondary structure motifs of wild-type Trichoplusia ni piggyBac transposase (SEQ ID NO: 2). See Figure 1We found that the piggyBac transposase is primarily an α-helical protein. We designed mutations that could potentially stabilize the α-helix, improving the overall stability of the transposase and, in turn, positively impacting its expression. We identified residues I147, I176, I221, and I247 as potential residues that could be mutated to improve the α-helical stability of the piggyBac transposase.
[0187] We also identified a putative N-linked glycosylation site (i.e., NXS / T motif) within the transposase sequence. Because NXT motifs are generally more fully glycosylated than NXS motifs, we hypothesized that mutating the NXS motif to an NXT motif might improve overall glycosylation on piggyBac and, in turn, transposase stability. The following Ser to Thr mutations were designed at the N-linked glycosylation site: N427ES, N531IS, and N571AS. The N531IS site is located within a hydrophobic region and, therefore, would likely provide the greatest stability improvement following improved glycosylation. It is currently unknown whether the piggyBac transposase is glycosylated or whether glycosylation is required for its activation.
[0188] A total of eight plasmids were generated, including nucleic acid sequences encoding wild-type piggyBac transposase and seven transposases encoding single, double, or triple mutations (see Table 3). Aside from the mutated sequences, these cloned transposase plasmids shared identical DNA codons. These transposase plasmids were transformed into a cell line, colonies were selected, cultured on a larger scale, and sequenced.
[0189] Table 3
[0190]
[0191] Four target proteins, two monoclonal antibodies (AB1 and AB2), a fusion protein, and a bispecific T cell engager were tested. Each gene encoding a target protein was cloned into a separate plasmid containing at least the 5' and 3' inverted repeat elements of the piggyBac transposon. These four plasmids were scaled up and sequence confirmed.
[0192] Circular mutant transposase plasmids were co-transfected into glutamine synthase knockout CHO cells using electroporation, along with one of the circular plasmids containing a gene encoding one of four proteins. The transposase to protein ratio was 1:4. The cells were allowed to recover in glutamine-supplemented medium at 36°C and 5% CO₂ for three days before switching to a selective medium lacking glutamine. The cells were passaged every three to four days in selective medium at 36°C and 5% CO₂ until viability reached >90%.
[0193] Fed-batch production was performed in 24 deep-well plates to evaluate protein expression from stable cell lines. Cultures were plated at 1x10 6 Cells / mL were seeded in basal production medium without glutamine and supplemented with nutrients on days 3, 6, and 8. Cultures were harvested on day 10, and the supernatants were analyzed for titer.
[0194] Titers were measured by affinity UPLC chromatography, where Protein A was immobilized on a column support at a target load of 20 μg. At neutral pH, proteins in the test sample bound to Protein A via the Fc region, while host cell proteins, conditioned media components, and buffer eluted from the column in the flow-through. The captured proteins were eluted in 1X DPBS at an acidic pH of 1.9 and detected by UV absorbance at 280 nm. A calibration curve was generated using linear regression analysis from universal antibody standards and corresponding peak areas. The concentration of the protein in the test sample was then calculated based on the calibration curve and the ratio of the extinction coefficients of the universal antibody standard and the test sample.
[0195] The use of mutant transposases demonstrated higher or similar titers compared to WT transposase or controls lacking transposase for the tested monoclonal antibodies and fusion proteins. Bispecific T cell engagers generally exhibit lower titers than monoclonal antibodies and are not typically expressed at high levels when used in this system. For this particular molecule, the expression bottleneck may not be related to transcription or gene integration sites, but rather to a protein secretion bottleneck. Other bispecific T cell engagers may yield different results if they do not face the same expression challenges, and therefore, using a different scaffold with the bispecific T cell engager molecule may yield better titers.
[0196] Example 2 Expression of double and triple transposase mutants in GS KO host cells supplemented with MSX
[0197] Glutamine synthase knockout CHO cells (GSKO cells) were transfected using electroporation (Bio-Rad, Hercules, CA) with circular plasmids encoding 1) double mutant "ILT" DNA piggyBac transposase (ITR, SEQ ID NO: 11), 2) triple mutant "LLT" DNA piggyBac transposase (LLT, SEQ ID NO: 9), and 3) no piggyBac transposase (None), in each case in combination with a circular plasmid containing the gene of interest and the 5' and 3' inverted repeat elements of the Trichoplusia ni piggyBac transposon. Three genes of interest were tested, a bispecific T cell engager heteroFc, an IgG-scFv, and a monoclonal antibody (mAb).
[0198] On day 3 post-transfection (25), after the initial pool had recovered to >90% viability (0-25) or not recovered at all (0), 25 μM methionine sulfoximide (MSX) (EDM Millipore, Burlington, MA) was added. The addition of methionine sulfoximide (MSX), an inhibitor of glutamine synthetase, was used to increase expression of the gene of interest in the GSKO CHO cell line.
[0199] After MSX-treated cells have recovered, they can be used for small-scale fed-batch production in 24-well plates or spin tubes to assess protein expression from stable cell lines. 6 Cells / mL were seeded in basal production medium without glutamine and supplemented on days 3, 6, and 8. Cultures were harvested on day 10 and the supernatants were analyzed for titer as described in Example 1.
[0200] Pools transfected with mutant transposase (ILT or LLT) showed increased expression compared to those transposase pools that did not receive MSX treatment (0 μM MSX). For those pools to which no transposase was added (None), expression did not increase with the addition of MSX.
[0201] Transposons confer a semi-targeted transfection mechanism that targets open chromatin, which are regions of active transcription in the genome. When a transposon integrates in conjunction with a transposase, the complete vector sequence between the 5' and 3' inverted repeat elements of the transposon is integrated. Transfection of a transposon without a transposase results in random integration into the chromosome, and as a result, the complete vector sequence between the 5' and 3' inverted repeat elements of the transposon may not be integrated into the active site. In addition, without a transposase, complete integration is not guaranteed, which may result in the disconnection between the gene of interest and the selection marker (glutamine synthase in this case), and thus MSX will not affect the expression of the gene of interest.
[0202] In the context of the vector systems tested, the engineered transposase had the additional advantage of increasing expression compared to the no-transposase control, both with and without the addition of MSX. Figure 5 The copy number gain from piggyBac may also help improve MSX selection.
[0203] Example 3 Transfection using DNA or mRNA piggyBac transposase.
[0204] The transposase used to integrate the gene of interest can be DNA- or mRNA-based. A concern with using DNA-transcribed transposases is the potential for the transposase gene to integrate into the genome, which can lead to active transcription / translation of the transposase in the transfected cell line. This can lead to genomic instability due to transposase activity at potentially cryptic transposase recognition sites. An alternative is to use mRNA for transfection, as it does not integrate into the genome.
[0205] For the double mutant "ILT" and triple mutant "LLT" piggyBac transposase, unmodified mRNA transcripts using wild-type bases and modified synthetic mRNA transcripts with 25% pseudo-U and 5-methyl-C capping substitutions were generated.
[0206] Two sets of experiments were performed to evaluate the mRNA translation transposase in transfection. In the first experiment, mRNA transcripts of the piggyBac transposase double mutant (ILT, SEQ ID NO: 17) and triple mutant (LLT, SEQ ID NO: 18) were tested. In the second experiment, in addition to these mRNA transcripts, synthetic mRNA transcripts of the double mutant "ILT" with 25% pseudo-U and 5-methyl C-terminal substitutions were also tested.
[0207] mRNA and synthetic mRNA transcripts are transfected into the GSKO cell line using electroporation or lipid-based transfection methods along with a circular plasmid containing the 5' and 3' inverted repeat elements of the Trichoplusia ni piggyBac transposon and a gene encoding a monoclonal antibody.
[0208] For electroporation, add equal weights of linearized transposase and transposon vector DNA to 2 x 10 7 cells. The DNA-cell mixture was electroporated using a Bio-Rad electroporator (Bio-Rad Laboratories). The electroporated cells were then added to warm growth medium and incubated at 37°C and 5% CO2 for 3 days, after which the cells were resuspended in selective medium to establish a stable pool. For the lipid transfection method, the reagent used was Lipofectamine LTX (Gibco / ThermoFisher, Waltham, MA). The day before transfection, cells were seeded at a rate of 1e6 cells / mL and shaken in suspension. On the day of transfection, cells were seeded in transfection medium into 6-well plates. Mab DNA / transposase / Lipofectamine LTX complexes were prepared and incubated. The complexes were then added to the cells and incubated for 5-8 hours. After incubation, growth medium was added and the cells were allowed to recover for 2-3 days. If adherence was present, the cells were removed using trypsin, centrifuged and resuspended in selective medium to establish a stable pool.
[0209] mRNA transfection was compared to control conditions in which the GSKO cell line was transfected with the corresponding DNA encoding the transposase. Circular plasmids containing DNA encoding the double mutant (ILT, SEQ ID NO: 11) or triple mutant (LLT, SEQ ID NO: 9) and a circular plasmid containing the 5' and 3' inverted terminal repeat elements of the Trichoplusia ni piggyBac transposon containing a monoclonal antibody were transfected under the same conditions as the mRNA.
[0210] The amounts of mRNA and DNA transposase, the target gene, the ratio of target gene DNA or RNA to transposase, and the number of cells transfected were varied to test the optimal conditions (see Table 4).
[0211] Table 4. Electroporation and lipofection conditions.
[0212]
[0213] The transfected cells were allowed to recover in glutamine-supplemented medium at 36°C and 5% CO2 for three days and then replaced with selective medium without glutamine. The cells were passaged every 3 to 4 days in selective medium at 36°C and 5% CO2 until viability of >90% was recovered and titered as described in Example 1.
[0214] Using electroporation-based or lipid-based transfection methods, transfection with mRNA achieved comparable expression levels as transfection with DNA of the piggyBac transposase double mutant "ILT." Figure 6 shows the expression levels of monoclonal antibodies from cells transfected with double mutant "ILT" transposase DNA or mRNA using electroporation or lipid-based methods. Figure 6A Results using electroporation are shown. Expression was increased compared to the DNA control due to an increase in the amount of mRNA. The triple mutant "LLT" gave similar results; data not shown. Figure 6B Results are shown for transfection using a lipid-based method. Expression levels of the monoclonal antibody were better or at least comparable to the DNA control.
[0215] The results for the synthetic mRNA were compared with those for the electroporated mRNA. Both forms showed higher expression than the control transfected without transposase (-).
[0216] Figure 7 Shown are monoclonal antibody expression levels relative to expression from electroporated double mutant transposase "ILT" DNA and two mRNA transfected pools. The titers of the synthetic mRNA and mRNA transfected pools were similar to those of the DNA-based transposase pool and higher than those of the no transposase control pool.
[0217] Analysis of genomic DNA-level integration of transposase genes.
[0218] The genomic DNA level integration of piggyBac transposase double mutant " ILT " and triple mutant " LLT " gene was also analyzed. Oligonucleotide primers at the 5' and 3' ends of the transposase nucleotide sequence were used, and these primers amplified a fragment of about 1.7kb to check whether the transposase exists. Blood and cell culture DNA Maxi test kit (Qiagen, Valencia, California) was used to extract genomic DNA from the cell mass of 1e7 cells collected in the recovery cell line transfected with mRNA or DNA. Plasmid DNA was used as a positive control. NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, Massachusetts) was used to carry out quantitative and quality control (≥1.8 is good quality) of the genomic DNA by 260 / 280 absorbance ratio. PCR amplification was carried out on ProFlex PCR system (Life Technologies, Carlsberg, California) using the Q5 high-fidelity polymerase from New England Biolab (Ipswich, Massachusetts). The reaction was run on an agarose gel for easy visualization.
[0219] Analysis of cDNA integration of transposase genes
[0220] The transcriptional integration of piggyBac transposase double mutant " ILT " gene was also analyzed. The fragment of about 1.7kb was amplified using the above-mentioned oligonucleotide primers again to check whether the transposase transcript is present in the cell. RNeasy mini kit (Qiagen) was used to extract mRNA from the cell mass of 1e7 cells collected in the recovery cell line transfected with added mRNA or DNA transposase. Plasmid DNA was used as a control. Quantitative mRNA was measured and its quality was checked by 260 / 280 absorbance ratio using a NanoDrop spectrophotometer. Transposase was checked at the transcriptional level using a SuperScript III one-step RT-PCR system (Thermo Fisher Scientific) with Platinum Taq high-fidelity DNA polymerase, on which cDNA synthesis was performed and target sequence (i.e., transposase) was amplified on a ProFlex PCR system (Life Technologies) according to the manufacturer's advice. The reaction was performed on an agarose gel for ease of observation.
[0221] The pool of cell lines transfected with DNA and mRNA was examined for integration at the genomic and transcriptional levels, see Figure 8. The presence of a band of approximately 1.7 kb indicates the presence of the transposase in the genome of this cell line, see Figure 8A All pooled cell lines transfected with the double mutant "ILT" DNA transposase had transcriptional integration, whereas those transfected with mRNA had no integration at either the genomic or transcriptional level, see Figure 8B .
[0222] ddPCR determination of copy number
[0223] To determine the copy number, 5×10 cells were isolated from each clone and pool using the DNeasy Blood and Tissue Kit (Qiagen). 6 Genomic DNA was extracted from 10 cells. Digital droplet PCR was performed using the ddPCR Supermix for Probes (dUTP-free) kit (Bio-Rad) according to the manufacturer's recommendations. Each reaction contained 1 unit of HindIII, 10 ng of template DNA, and 900 nm of forward and reverse primers, as well as 250 nm of fluorescent probes designed to target the double mutant "ILT" coding sequence and the endogenous CHO reference gene Gcg. Droplets were generated using the AutoDG system (Bio-Rad), and PCR amplification was performed on the ProFlex PCR system (Life Technologies) using thermal cycling conditions of 95°C for 10 minutes, followed by 40 cycles of 94°C for 30 seconds and 60°C for 1 minute, followed by 98°C for 10 minutes. Droplets were read on the QX200 Droplet Reader system (Bio-Rad), and copy number data were analyzed using Quantasoft software (Bio-Rad).
[0224] To determine whether all clones in the pool had integrated the transposase, pools transfected with DNA transposase were single-cell cloned and examined for integration at the genomic DNA (gDNA) level. ddPCR was also used to determine the transposase copy number of the pool and these clones.
[0225] This pool has a lower copy number and contains clones that have not integrated the transposase. As described above, clones without transposase integration were screened using a PCR-based method to identify clones without transposase integration. Figure 9 .
[0226] Example 4 Generation of TCR-T cells using piggyBac transposase
[0227] Primary T cells were successfully modified to express T cell receptors (TCRs) using the double-mutant piggyBac transposase "ILT". Figure 10A TCR-T cells generated by PiggyBac exhibit robust target killing and antigen-specific proliferation ( Figure 10B and 10C ).
[0228] Peripheral blood mononuclear cells (PBMCs) were first isolated from healthy donor leukopaks by Ficoll-Paque (GE Healthcare, Chicago, IL), and T cells were subsequently isolated from PBMCs using the EasySep Human T Cell Isolation Kit (Stemcell Technologies, Vancouver, Canada). T cells were then activated and, two days after activation, co-electroporated with a plasmid containing the 5' and 3' inverted terminal repeat elements of the piggyBac transposon encoding the gene for TCR-IRES-EGFP and mRNA for the double mutant "ILT" transposase (SEQ ID NO: 18) using the 4-D Nucleofection System (Lonza, Greenwood, SC). Cells were supplemented with IL2 cytokine every 2-3 days.
[0229] Determination of TCR integration
[0230] On day 7 after activation, T cells were surface stained with a TCR-recognizing right-handed antibody (Immudex, Copenhagen, Denmark) and CD3, CD4, and CD8 fluorophore-conjugated antibodies (Biolegend, San Diego, CA) to assess TCR expression and cell phenotype. Samples were analyzed by running on a BD LSRII flow cytometer.
[0231] Functional assays
[0232] On days 9-14 after activation, T cells were counted and collected for functional assays.
[0233] Cell lysis and proliferation assays
[0234] In 96-well U-bottom plates, 1E5 CellTrace Violet (ThermoFisher Scientific, Waltham, MA)-stained T cells were incubated with 5e4 target cells in 150 μL of culture medium for 5 days. Target cell lysis and T cell proliferation were assessed by CellTrace Violet, and dilutions were quantified by running samples on a BDLS RFortessa flow cytometer (Liberty Lake, WA).
Claims
1. A piggyBac transposase comprising an amino acid substitution at one or more of positions 147, 176, 221, 247, 429, 533 and 573 of SEQ ID NO:
2.
2. The piggyBac transposase of claim 1, comprising an amino acid substitution of leucine for isoleucine at one or more of positions 147, 176, 221 and 247 of SEQ ID NO: 2, and / or an amino acid substitution of threonine for serine at one or more of positions 429, 533 and 573 of SEQ ID NO:
2.
3. The piggyBac transposase of claim 2, comprising at least two of the following amino acid substitutions: an amino acid substitution of leucine for isoleucine at position 147 of SEQ ID NO:2, an amino acid substitution of leucine for isoleucine at position 247 of SEQ ID NO:2, and an amino acid substitution of threonine for serine at position 533 of SEQ ID NO:
2.
4. The piggyBac transposase of claim 1, wherein the titer of the recombinant protein of interest expressed by cells transfected with the engineered piggyBac transposase is improved compared to the titer of the same protein of interest expressed by cells transfected with wild-type piggyBac transposase or not transfected with piggyBac transposase.
5. A piggyBac transposase having the amino acid sequence of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14 or SEQ ID NO:
16.
6. An engineered nucleic acid molecule encoding the piggyBac transposase according to claim 1 or 5.
7. A piggyBac transposase encoded by the nucleic acid sequence of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17 or SEQ ID NO:
18. 8 . A vector comprising the nucleic acid molecule encoding the piggyBac transposase according to claim 6 or the nucleic acid molecule encoding the piggyBac transposase according to claim 7 .
9. A cell transfected with the piggyBac transposase encoded by the nucleic acid sequence according to claim 7.
10. A cell transfected with the vector according to claim 8.
11. The cell according to claim 9 or 10, wherein the cell is a CHO cell.
12. A cell co-transfected with a vector comprising an engineered nucleic acid molecule encoding a piggyBac transposase according to claim 8 and a vector comprising at least one nucleic acid molecule encoding at least one protein of interest, wherein the at least one nucleic acid molecule is flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon.
13. The method of any one of claims 9, 10 or 12, wherein the titer of the protein of interest expressed by cells transfected with the engineered piggyBac transposase is improved compared to the titer of the same protein of interest expressed by cells transfected with wild-type piggyBac transposase or not transfected with piggyBac transposase.
14. A method for increasing the production of a recombinant protein in a mammalian cell culture expressing the recombinant protein, the method comprising establishing a cell culture in a bioreactor using a host cell, wherein the host cell has been co-transfected with a nucleic acid molecule encoding a piggyBac transposase engineered for increased stability in the host cell and flanked by at least an inverted repeat element of the piggyBac transposon, and a vector comprising a nucleic acid molecule encoding a protein of interest; and Expressing the target recombinant protein; The titer of the target recombinant protein expressed by the host cells transfected with the engineered piggyBac transposase is improved compared to the titer of the target recombinant protein expressed by the host cells transfected with the wild-type piggyBac transposase or not transfected with the piggyBac transposase.
15. The method of claim 14, wherein the host cell is transfected with a first vector comprising the engineered nucleic acid molecule encoding the piggyBac transposase and a second vector comprising a nucleic acid sequence encoding a protein of interest, said nucleic acid sequence being flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon.
16. A method for producing a recombinant protein of interest, separated and purified, comprising: establishing a cell culture in a bioreactor with a host cell expressing a recombinant protein of interest, wherein the cell line has been co-transfected with a nucleic acid sequence encoding a piggyBac transposase engineered for increased stability in the host cell and flanked by at least 5' and 3' inverted repeat elements of the piggyBac transposon, together with a vector comprising a nucleic acid sequence encoding the protein of interest; The cells are cultured to express the target recombinant protein; The target recombinant protein is harvested. processing the target recombinant protein through one or more unit operations, and Obtain the separated and purified target recombinant protein.
17. The method of claim 16, wherein the host cell is transfected with a first vector comprising the engineered nucleic acid molecule encoding the piggyBac transposase and a second vector comprising a nucleic acid sequence encoding a protein of interest, said nucleic acid sequence being flanked by at least the 5' and 3' inverted repeat elements of the piggyBac transposon.
18. The method of claim 16, wherein the titer of the recombinant protein of interest expressed by host cells transfected with the engineered piggyBac transposase is improved compared to the titer of the recombinant protein of interest expressed by host cells transfected with wild-type piggyBac transposase or not transfected with piggyBac transposase.
